curriculum vitae christopher jon kratochvil, md unmc cv 2015.pdfcurriculum vitae christopher jon...

Christopher J. Kratochvil, M.D. 2020

1

Curriculum Vitae Christopher Jon Kratochvil, MD

CAMPUS ADDRESS: Vice Chancellor for Research

987878 Nebraska Medical Center Omaha, NE 68198-7878 Phone: (402) 559-8480 Fax (402) 559-8445 E-mail: [email protected]

EDUCATION 1987 – 1997 M.D., Doctor of Medicine, Creighton University, Omaha, NE 1983 – 1987 B.A., Psychology, Creighton University, Omaha, NE POST DEGREE TRAINING 1996 – 1997 Chief Resident in Child & Adolescent Psychiatry, Duke University Medical

Center, Durham, NC 1995 – 1997 Resident in Child & Adolescent Psychiatry, Duke University Medical

Center, Durham, NC 1994 – 1995 Associate Chief Resident in Psychiatry, Creighton-Nebraska University,

Omaha, NE 1992 – 1995 Resident in Psychiatry, Creighton-Nebraska University, Omaha, NE ACADEMIC APPOINTMENTS 2018 – Present Core Competency Advisor for Active and Passive Medical Defense

against Weapons of Mass Destruction and Consequence Management, National Strategic Research Institute

2012 – Present Associate Vice Chancellor for Clinical Research, University of Nebraska Medical Center, Omaha, NE

2014 – Present Vice President for Research, Nebraska Medicine, Omaha, NE 2010 – Present Chief Medical Officer, UNeHealth, Omaha, NE February 2017 – Present Institutional Official, Human Research Protection Program, UNMC,

University of Nebraska at Omaha, Nebraska Medicine, Children’s Hospital & Medical Center

2017 – Present Exec Council Global Health for Security Center 2016 – Present Professor, COPH, Dept Environmental Agriculture and Occupational

Health (Courtesy) 2010 – 2012 Assistant Vice-Chancellor for Clinical Research, UNMC 2012 – Present Director, Nebraska Biobank, UNMC 2012 – Present Director, Clinical Research Center, UNMC 2009 – Present Clinical Professor, Psychiatry, Creighton University School of Medicine,

Omaha, NE 2008 – Present Professor, Psychiatry, UNMC 2008 – Present Professor, Pediatrics (Courtesy), UNMC 2008 – 2010 Director, Division of Child & Adolescent Psychiatry, University of

Nebraska Medical Center, Omaha, NE 2009 – 2010 Clinical Service Chief, Child & Adolescent Psychiatry, Children’s Hospital

and Medical Center 2009 – 2010 Faculty Associate, UNMC Center for Humanities, Ethics & Society


2

2003 – 2008 Associate Professor, Psychiatry, University of Nebraska Medical Center, Omaha, NE

2005 – 2008 Associate Professor, Pediatrics (Courtesy), University of Nebraska Medical Center, Omaha, NE

2001 – Present Graduate Faculty, University of Nebraska 2006 – 2007 Interim Director, Psychopharmacology Research Consortium, University

of Nebraska Medical Center, Omaha, NE 2000 –2010 Assistant Director, Psychopharmacology Research Consortium,

University of Nebraska Medical Center, Omaha, NE 2006 – Present Faculty Affiliate, Nebraska Center for Research on Children, Youth,

Families and Schools, University of Nebraska, Lincoln, NE 1999 – 2003 Assistant Professor, Psychiatry, University of Nebraska Medical Center,

Omaha, NE 1999 – 2005 Clinical Assistant Professor, Psychiatry, Creighton University, Omaha, NE 1998 – 1999 Assistant Professor, Psychiatry, Creighton University School of Medicine,

Omaha, NE 1998 – 1999 Medical Director, Residential Treatment Center, Saint Joseph Center for

Mental Health, Omaha 1997 – 1999 Director, Outpatient Services, Division of Child & Adolescent Psychiatry,

Creighton-Nebraska Department of Psychiatry, Omaha, NE 1997 – 1998 Instructor, Psychiatry, Creighton University School of Medicine, Omaha,

NE 1997 – 1998 Co-Director, Behavioral Pediatrics Clinic, Creighton University

Department of Pediatrics, Omaha, NE 1997 – 1999 Clinical Instructor, Psychiatry, University of Nebraska Medical Center,

Omaha, NE BOARD CERTIFICATE AND LICENSES 1993 - Present Nebraska State Board of Medical Examiners, M.D., License #19242 1999 – 2009 American Board of Psychiatry & Neurology, Added Qualifications in Child

& Adolescent Psychiatry 1998 – 2008 American Board of Psychiatry & Neurology, in Psychiatry, 1998 GRANT AND CONTRACT SUPPORT

Centers for Disease Control and Prevention & U.S. Dept. of HHS Office of the Assistant Secretary for Preparedness

HHSO100201700005C Kratochvil, Lowe, and Schwedhelm (Co-PIs) 10/31/16-10/30/20 U.S. Department of Health and Human Services Training, Simulation and Quarantine Service (TSQC) In response to West Africa’s largest Ebola virus disease outbreak in 2014, the goal of this

funding is to provide training and quarantine services in a Training, Simulation and Quarantine Center to train U.S. Government and other appropriate personnel for another outbreak of Ebola or other highly pathogenic disease and to provide a facility to quarantine individuals exposed to such diseases. $19,800,000

National Ebola Training and Education Center. UNMC Co-PIs: Kratochvil & Lowe. U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response and Centers for Disease Control and Prevention National Center for Emerging and Zoonotic, Infectious Diseases, (EP-U3R-15-003t). 2015-2020. $24,000,000.


3

Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities (CFDA #93.817). PI: Kratochvil. U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness, (EP-U3R-15-002). 2015-2020. $4,250,000.

Public Health Emergency Preparedness Program. PI: Kratochvil. U.S. Centers for Disease Control and Prevention, (U90TP000533) 2015-2016. $936,000

Clinical Training Assessment Support for Ebola Treatment Facilities. PI: Kratochvil. Centers for Disease Control and Prevention, (200-2015-61472). 2014-2015. $800,000.

National Institutes of Health Grants A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in

the Treatment of Patients with Known Ebola Infection; National Institute of Allergy and Infectious Diseases, 2015-Present; Site PI: Kratochvil

Innovative Device to Improve Safety of Preparing and Administering Chemotherapy (2R44CA153636-02) 2012-2014; Site Investigator: Kratochvil

Automated Interactive Text Messaging to Assess Adolescent Depression (2R44MH086152) 2012; Consultant: Kratochvil

Computerized Screening for Comorbidity in Adolescents with Substance or Psychiatric Disorders; National Institutes of Health (1R43MH94092-01) 2011-2012; Site PI: Kratochvil

Enhancing Pediatric Psychopharmacology in the Medical Home; National Institutes of Health, (1 RC1 MH088922-01) 2009-2011; PI: Peter Jenson, M.D., Co-Investigator: Kratochvil

Prevention of Depression in Patients Being Treated for Head and Neck Cancer; National Institutes of Health, 2007-2012; PI: William Burke, M.D., Co-Investigator: Kratochvil

Substance Use Outcomes Following Treatment for Adolescent Depression (SOFTAD); National Institute of Mental Health, Subcontract through Duke University, 2004-2009; PI: Kratochvil

Pharmacological Treatment of ADHD in Young Children, a Mentored Patient-Oriented Research Career Development Award (K-23) in Response to PA-00-004. (5K23MH066127-03) 2003-2009; PI: Kratochvil

Genetic Linkage Study of Children with Attention Deficit Hyperactivity Disorder; National Institute of Mental Health, Subcontract through Harvard Medical School, 2003-2006; PI: Kratochvil

Treatment for Adolescents with Depression Study (TADS); National Institute of Mental Health, Subcontract through Duke University, 1999-2005; Site PI: Kratochvil

A Multi-Center Study of the Validity, Reliability, and Consumer Satisfaction of the Pediatric Adverse Event Rating Scale (PAERS): A Likert-Style Adverse Event Reporting Questionnaire; National Institute of Mental Health, Subcontract through Duke University, 2005; Site PI: Kratochvil start and end date is 2005?

PCORI Greater Plains Collaborative for Comparative Research; UNMC PI: James McClay; UNMC

Steering Committee Member Kratochvil National Center for Research Resources IRB Training through a Web-Based Protocol Review Form; NIH S07 Award, 2003-2004; PI:

Ernest Prentice, Ph.D., Co-Investigator: Kratochvil State and Local Grants Genetic and Biochemical Markers in Children with ADHD; John A. Weibe, Jr. Children’s

Healthcare Fund, 2000- 2003; PI: Kratochvil Genetic and Biochemical Markers in Children with ADHD; UNMC College of Medicine

Translational/Collaborative Grant, 2000-2003; PI’s: David Bylund, Ph.D., Shelley Smith, Ph.D., Kratochvil


4

Candidate Genes in Drug Responsive Children with ADHD; Ittner Foundation, 2000-2002; PI: Cindy Ellis, M.D., Co-Investigator: Kratochvil, et al.

Contracts OTHER GRANTS AND CONTRACTS

1. A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients with Known Ebola Infection. NIAID, 2015-present, Site PI: Kratochvil.

2. A Prospective, Open Label, Observational Phase 1 Safety Study of Passive Immune Therapy during Acute Ebola Virus Disease using Transfusion of INTERCEPT Plasma Prepared from Volunteer Donors who have Recovered from Ebola Virus Disease, Protocol # CLI 00113, 2014-Present, Secondary Investigator: Kratochvil

3. Treatment Protocol for Emergency Use of TKM-100802 for Injection, 2014, Secondary Investigator: Kratochvil

4. Emergency Use of a Recombinant Vesicular Stomatitis Virus Expressing the Envelope Glycoprotein of Ebolavirus Zaire (VSVÄG-ZEBOV) Vaccine for Post-Exposure Prophylaxis for Ebola virus Exposure, 2014-Present, Secondary Investigator: Kratochvil

5. Nebraska Biocontainment Unit Biobank. 2014-Present PI: Kratochvil 6. Convalescent Plasma Transfusion for Ebola Virus, 2014, Secondary Investigator:

Kratochvil. 7. Rural healthcare disparity: Patient activation and obesity, Rural Futures Institute.

2014-2015, PI: Kratochvil. 8. The use of psychotropic medication and therapeutic services by children and

adolescents enrolled in Nebraska Medicaid. 2014-Present. PI: H. Kimball; Participating Personnel Kratochvil.

9. A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients with Major Depressive Disorder (VLZ-MD-21). Forest 2013-2014, PI: Kratochvil

10. A Phase 4, Randomized, Double-Blind, Multicenter, Parallel Group, Active-Controlled, Dose-Optimization Safety and Efficacy Study of SPD489 (Vyvanse) Compared with OROS-MPH (Concerta) with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with ADHD. Shire, 2012-2014, PI: Kratochvil

11. A Phase 3, Randomized, double-blind, Multicenter, Parallel-group, Placebo- and Active Reference, Dose Optimization Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder. Shire, 2011-2014, PI: Kratochvil

12. A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents with Generalized Anxiety Disorder (F1J-MC-HMGI). Eli Lilly, 2011-2013, PI: Kratochvil

13. A Phase 3, Double-Blind, Placebo-controlled, Multicenter, Randomized-withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder. Shire, 2010-2013, PI: Kratochvil

14. Long-Term, Open-Label, Safety Study of LY2216684 in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder (H9P-MC-LNDH), Eli Lilly & Company, 2009-2010, PI: Kratochvil

15. A Fixed-Dose, Randomized, Double-blind, Placebo-Controlled Study of LY2216684 in Children and Adolescents with Attention Deficit/Hyperactivity Disorder (H9L-MC-LNBF), Eli Lilly & Company, 2009-2010, PI: Kratochvil


5

16. Effect of LY450139, a -secretase Inhibitor, on the Progression of Alzheimer’s Disease as Compared with Placebo (H6L-MC-LFBC), Eli Lilly & Company, 2009, Co-Investigator: Kratochvil

17. Long-Acting Stimulant Treatment of ADHD in Young Children, Schlosser Lewis Fund, 2009, Co-Investigator: Kratochvil

18. A Double-Blind, Efficacy and Safety Study of Duloxetine versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder (F1J-MC-HMCK), Eli Lilly & Company, 2009, PI: Kratochvil

19. A Long-Term, Open-Label, Extension Study of Escitalopram in Adult Patients With Major Depressive Disorder (SCT-MD-50), Forest, 2008-2009, Co-Investigator: Kratochvil

20. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of 0.7 mg/kg/day and 1.4 mg/kg/day of ABT-089 in the Treatment of Children with ADHD (M10-345) PI: Kratochvil

21. The Long-term Safety and Tolerability of ABT-089 in Children with Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study (M10-178), Abbott, 2007–2008. PI: Kratochvil

22. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Children with Attention Deficit-Hyperactivity Disorder (ADHD) (M06-888), Abbott, 2007-2008. PI: Kratochvil

23. A Double-Blind Study of Atomoxetine Hydrochloride versus Placebo for the Treatment of ADHD in Young Adults with an Assessment of Associated Functional Outcomes (B4Z-US-LYDZ), Eli Lilly & Company, 2007-2008, Co-Investigator: Kratochvil

24. A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible-Dose Study of the Safety and Efficacy of EMSAM® in Adolescents with Major Depression (S9303-P0605), Somerset, 2007-2009, PI: Kratochvil

25. A 52-Week, Randomized, Double-blind, Placebo-Controlled, Multi-Centre, Parallel-Group Study of the Long-Term Efficacy, Tolerability and Safety of Agometlatine 25 and 50 mg in the Prevention of Relapse of Major Depressive Disorder (MDD) Following Open-Label Treatment of 16-24 Weeks (CAGO178A2304), Novartis, 2007–2009. Co-Investigator: Kratochvil et al

26. Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients (SCT-MD-39), Forest Research Institute, 2007–2008. Co-Investigator: Kratochvil et al

27. Open Label, Flexible Dose 12-Week Clinical Trial of the Safety and Efficacy of Acamprosate in the Treatment of 15 Subjects With Pathological Gambling, Forest Research Institute, 2007–2008. Co-Investigator: Kratochvil, et al

28. A Double-Blind, Randomized, Multi-Center Flexible Dose Study Evaluating the Efficacy and Safety of SPD503 in Children Aged 6-12 with Symptoms of Oppositionality and a Diagnosis of Attention-Deficit/Hyperactivity Disorder (SPD503-307), Shire, 2007–2008. PI: Kratochvil

29. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy of ABT-089 in Adults with Attention Deficit-Hyperactivity Disorder (ADHD) (M06-855), Abbott Laboratories, 2007–2008 PI: Kratochvil

30. The Long-Term Safety and Tolerability of ABT-089 in Adults with Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study (M06-889), Abbott Laboratories, 2007–2008. PI: Kratochvil

31. An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA® at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg per day in Adults with Attention Deficit Hyperactivity Disorder (12-304), McNeil, 2006-2007. PI: Kratochvil

32. Caloric Supplementation During Long-Term Pharmacological Treatment of ADHD in Young Children, 2006–2010, PI: Kratochvil


6

33. A Comparison of Face-To-Face And Remote Administration Of The Child Depression Rating Scale (CDRS) Via Videoconferencing, 2006–2007, PI: Kratochvil

34. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling (SP-N0406), 2005-2006. Co-Investigator: Kratochvil, et al

35. An 8-week, Open-Label Study to Characterize the Response to Modafinil (85-mg Film-Coated Tablet) Treatment at Dosages up to 425 mg/day in Children & Adolescents with ADHD (With an Open-Ended Extension Period) (C1538/3044/AD/US), 2005-2007. PI: Kratochvil

36. Tolerability and Cost Effectiveness of Escitalopram in Adult Patients With Major Depressive Disorder (SCT-MD-23A), Forest Research Institute, 2005-2006; PI: Steven Wengel, M.D., Co-Investigator: Kratochvil, et al.

37. Fixed Dose Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder (SCT-MD-35), Forest Research Institute, 2005-2006; PI: Steven Wengel, M.D., Co-Investigator: Kratochvil, et al.

38. Double-Blind Study of Escitalopram in Adult Patients with Major Depressive Disorder (SCT-MD-23) Forest Research Institute, 2005-2006; PI: Steven Wengel, M.D., Co-Investigator: Kratochvil, et.al.

39. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer’s Disease (030-00); Merck, 2003-2006; PI: William Burke, M.D., Co-Investigator: Kratochvil, et.al.

40. A 7-Month, Multicenter, Parallel, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended Release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-Up Phase (GSK-100006); GlaxoSmithKline, 2003-2004; PI: William Burke, M.D., Co-Investigator: Kratochvil, et.al.

41. A 1-Year, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Continued Efficacy of Modafinil (Film-Coated Tablet Formulation) in Children and Adolescents with Attention Deficit Hyperactivity Disorder (C1538/312/AD/US); Cephalon, 2003-2005; PI: Kratochvil

42. A 9-Week, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dosage (up to 425 mg/day), Parallel-Group Study to Evaluate the Efficacy and Safety of Modafinil Film-Coated Tablet in Children and Adolescents with Attention Deficit Hyperactivity Disorder (1538/311/AD/US); Cephalon, 2003-2005; PI: Kratochvil

43. Depression Response to Eszopiclone in Adults with Major Depressive Disorder (DREAMDD): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety and Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects with Insomnia Related to Major Depressive Disorder (190-0520); Sepracor, 2003; Co-Investigator: Kratochvil

44. A Double-Blind Flexible Dose Comparison of Escitalopram, Sertraline, and Placebo in the Treatment of Major Depressive Disorder (SCT-MD-27); Forest Research Institute, 2003-2004; PI: William Burke, M.D., Co-Investigator: Kratochvil

45. A Double-Blind Flexible Dose Comparison of Escitalopram, Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder (SCT-MD-31); Forest Research Institute, 2003-2004; PI: William Burke, M.D., Co-Investigator: Kratochvil

46. A Double-Blind, Flexible-Dose Comparison of the Safety and Efficacy of Escitalopram and Placebo in the Treatment of Geriatric Depression (SCT-MD-13); Forest Laboratories, 2003-2004; PI: William Burke, M.D., Co-Investigator: Kratochvil

47. A Three-Phase Study to Develop a Parent-Report Measure of the Impact of Psychopharmacologic Intervention on the Expression of Personality in Children ages 6-12 with ADHD; Lilly, 2003-2005; PI: Kratochvil


7

48. A 6½ Month, Multicenter, Randomized, Double-blind, Placebo-Controlled Comparison of 150-300mg/day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder (AK130930); GlaxoSmithKline, 2002-2003; PI: William Burke, M.D., Co-Investigator: Kratochvil

49. An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Comparison of Extended-release Bupropion Hydrochloride 300-450 mg/day to Assess the Efficacy, Safety and Effects on Health Outcomes in the Treatment of Adults with Attention-Deficit-Hyperactivity-Disorder (AK130934); GlaxoSmithKline, 2002-2003; PI: Kratochvil

50. An Open-Label Extension Study of the Long-Term Safety of Neramexane in Patients with Major Depressive Disorder (NER-MD-22); Forest Laboratories, 2002-2003; PI: William Burke, M.D., Co-Investigator: Kratochvil

51. Double-Blind Flexible Dose Comparison of the Safety and Efficacy of Neramexane and Placebo in the Treatment of Major Depressive Disorder (NER-MD-21); Forest Laboratories, 2002-2003; PI: William Burke, M.D., Co-Investigator: Kratochvil

52. A Double-Blind Placebo-Controlled Evaluation of the Safety and Efficacy of Escitalopram in Pediatric Depression (SCT-MD-15), Forest Laboratories, 2003-2004; PI: Kratochvil

53. A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride, Extended-Release Methylphenidate Hydrochloride (Concerta ™) and Placebo in Pediatric Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder (B4Z-MC-LYBI); Eli Lilly and Company, 2002-2004; PI: Kratochvil

54. Dose Escalation, Double-Blind Treatment with Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression (F1J-US-HMBY); Eli Lilly and Company, 2002-2003; PI: William Burke, M.D.; Co-Investigator: Kratochvil

55. A Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Efficacy of MK-0869 in the Maintenance of Antidepressant Effect in Geriatric Outpatients with Major Depressive Disorder (Merck 068-00); Merck, 2002-2004; PI: William Burke, M.D.; Co-Investigator: Kratochvil

56. An Open-Label Extension Study of the Safety and Eff icacy of Escitalopram in Patients with Major Depressive Disorder (SCT-MD-19); Forest Laboratories Inc., 2002-2004; PI: William Burke, M.D.; Co-Investigator: Kratochvil

57. An Evaluation of the Safety and Efficacy of Concerta® (Up to 72 Mg Daily) in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) (01-146); McNeil Pharmaceutical, 2002-2004; PI: Kratochvil

58. Two-Week Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Severe Major Depression Phase A: Double-Blind Comparison of the Safety and Efficacy of Escitalopram and Placebo after Two Weeks of Treatment of Patients with Severe Major Depression Phase B: Double-Blind Comparison of the Safety and Efficacy of Escitalopram and Placebo after Eight Weeks of Treatment of Patients with Severe Major Depression (SCT-MD-26); Forest Laboratories, Inc., 2001-2003; PI: William Burke, M.D., Co-Investigator: Kratochvil

59. A Long-Term Extension Study Evaluating the Safety and Tolerability of Four Memantine Dosing Regimens in Patients with Moderate to Severe Dementia of the Alzheimer’s Type (MEM-MD-03); Forest Laboratories, 2001-2005; PI: William Burke, M.D., Co-Investigator: Kratochvil

60. A Phase 4, Double-Blind, Placebo-Controlled Trial of Atomoxetine Hydrochloride to Evaluate Efficacy in the School Setting in Children Ages 8 to 12 Years with Attention Deficit/Hyperactivity Disorder (LYAW); Eli Lilly and Company, 2001-2003; PI: Kratochvil


8

61. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Moderate to Severe Dementia of the Alzheimer’s Type (MEM-MD-01); Forest Laboratories, Inc., 2001-2003; PI: William Burke, M.D., Co-Investigator: Kratochvil

62. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Moderate to Severe Dementia of the Alzheimer’s Type (MEM-MD-02); Forest Laboratories, Inc., 2001-2002; PI: William Burke, M.D., Co-Investigator: Kratochvil

63. Fixed Dose Continuation Study of Escitalopram in the Treatment of Depressed Nonresponders (SCT-MD-08); Forest Laboratories, Inc., 2001-2002; PI: William Burke, M.D., Co-Investigator: Kratochvil

64. Flexible Dose Comparison of the Safety and Efficacy of Escitalopram and Placebo in the Treatment of Generalized Anxiety Disorder (SCT-MD-06); Forest Laboratories, Inc., 2001-2002; PI: William Burke, M.D., Co-Investigator: Kratochvil

65. An Open-Label Extension Study of the Safety and Efficacy of LU 26-054 in Patients with Generalized Anxiety Disorder (SCT-MD-17); Forest Laboratories Inc, 2001-2002; PI: William Burke, M.D.; Co-Investigator: Kratochvil

66. Safety and Efficacy of Tomoxetine or Tomoxetine plus Fluoxetine in the Treatment of Mixed Attentional and Affective Disorders (LYAQ); Eli Lilly and Company, 2000-2002; PI: Kratochvil

67. A Phase III Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges (mg/kg/day) of Tomoxetine with Placebo in Child and Adolescent Outpatients with ADHD, Aged 8 to 18 Years (LYAC); Eli Lilly and Company, 2000-2002; PI: Kratochvil

68. Efficacy, Tolerability, and Safety of Once-Daily Tomoxetine Hydrochloride versus Placebo in Children with ADHD (LYAT); Eli Lilly and Company, 2000-2002; PI: Kratochvil

69. Long-Term, Open-Label, Safety Study of Tomoxetine Hydrochloride in Patients, 6 years and Older (LYAI); Eli Lilly and Company, 2000-Present; PI: Kratochvil

70. A Phase III Open-Label Safety and Efficacy Study of Tomoxetine Hydrochloride in Outpatients with ADHD Ages 6 to 18 Years (LYAB); Eli Lilly and Company, 2000-2003; PI: Kratochvil

71. Video Recording of Hamilton Rating Scale for Depression (HRSD) Assessments for Patients Enrolled in Cyberonics Protocol D-02 Study of the Neurocybernetic Prosthesis (NCP©) System in Patients With Depression (D-05); Cyberonics, 2000-2002; PI: William Burke, M.D., Co-Investigator: Christopher Kratochvil, M.D., et al.

72. Immune Function in Treatment Resistant Depression; UNMC, 2000-2002; PI: William Burke, M.D., Co-Investigator: Kratochvil

73. Evaluation of the Safety and Efficacy of Lu 26-054 in the Prevention of Depression Recurrence (SCT -MD-11); Forest Laboratories, Inc., 2000-2002; PI: William Burke, M.D., Co-Investigator: Kratochvil

74. A Multi-Center, Pivotal, Safety and Efficacy Study of the Neuro Cybernetic Prosthesis (NCP®) System in Patients with Depression (D-02); Cyberonics, 2000-2005; PI: William Burke, M.D., Co-Investigator: Kratochvil

75. Open Label Use of Synthetic Galantamine in the Treatment of Alzheimer’s Disease (GAL-USA-18); Janssen Pharmaceuticals, 2000-2002; PI: William Burke, M.D., Co-Investigator: Kratochvil

76. Tomoxetine Hydrochloride: Randomized, Double-Blind, Placebo-Controlled, Variable Discontinuation Study in Children with Attention-Deficit/Hyperactivity Disorder (HFBE); Eli Lilly and Company, 1998-2000; PI: Kratochvil

77. Fluoxetine versus Placebo in the Treatment of Children and Adolescents with Obsessive Compulsive Disorder; Eli Lilly and Company, 1999-2000; PI: Kratochvil


9

78. Double-Blind, Multicenter, Dose-Finding Acute and Extension Study of L-759,274 Versus Paroxetine Hydrochloride and Placebo in the Treatment of Outpatients with Major Depressive Disorder; Merck, 1999-2000; PI: William Burke, M.D., Co-Investigator: Christopher Kratochvil, M.D., et al.

79. Long-Term Safety of Galantamine in the Treatment of Alzheimer’s Disease (GAL-USA-12); Janssen Pharmaceutical, 1999-2001; PI: William Burke, M.D., Co-Investigator: Kratochvil

80. Safety and Efficacy of Galantamine during Withdrawal in the Treatment of Alzheimer’s Disease (GAL-USA-11); Janssen Pharmaceutical, 1999-1999; PI: William Burke, M.D., Co-Investigator: Kratochvil

81. A Placebo-Controlled Trial of Citalopram in the Treatment of Major Depressive Disorder with Evaluation of the Effects of Treatment on Natural Killer Cell Activity; Forest Laboratories, 1999-2002; PI: William Burke, M.D., Co-Investigator: Kratochvil

82. Placebo-Controlled Evaluation of Safety and Efficacy of LU 26-054 in the Prevention of Depressive Relapse (SCT-MD-03); Forest Laboratories, 1999-2001; PI: William Burke, M.D.; Co-Investigator: Kratochvil

83. Fixed Dose Comparison of the Safety and Efficacy of Lu 26-054, Citalopram, and Placebo in the Treatment of Major Depressive Disorder (SCT-MD-01); Forest Laboratories, 1999-2000; PI: William Burke, M.D., Co-Investigator: Kratochvil

84. Long-Term, Open-Label, Safety Study of Tomoxetine Hydrochloride in Patients, 6 Years and Older (HFBF); Eli Lilly and Company, 1998-2002; PI: Kratochvil

85. Placebo Controlled Evaluation of Galantamine in the Treatment of Alzheimer’s Disease: Safety and Efficacy Under a Slow-Titration Regimen (GAL-USA-10); Janssen Pharmaceutical, 1998-1999; PI: William Burke, M.D., Co-Investigator: Kratochvil

86. A Randomized, Double-Blind Study of Tomoxetine Hydrochloride, Methylphenidate Hydrochloride, and Placebo in Pediatric Outpatients with ADHD (HFBK); Eli Lilly and Company, 1998-2001; PI: Kratochvil

87. Rapid Titration of Sodium Valproate in Adolescent Mood Lability; Abbott Laboratories, 1997-1998; PI: Kratochvil

88. A Randomized, Double-Blind, Placebo-Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of 20 and 40 mg/day Paroxetine in Patients with Generalized Anxiety Disorder; SmithKline Beecham, 1998-1999; PI: William Burke, M.D., Co-investigator: Kratochvil

89. Enteric-Coated Fluoxetine Hydrochloride Versus Daily Fluoxetine or Placebo in the Continuation Treatment of Major Depressive Disorder; Eli Lilly and Company, 1997-1998; PI: William Burke, M.D., Co-investigator: Kratochvil

90. Paroxetine in Pediatric O.C.D.; SmithKline Beecham, 1997-1998; PI: Humberto Quintana, M.D., Co- Investigator: Kratochvil

91. Dextroamphetamine Dosing in Pediatric A.D.H.D.; Departmental Funding, 1996-1997; PI: Kratochvil, Co-Principal Investigator John March, M.D., M.P.H.

92. Buspirone Patch in Pediatric A.D.H.D.; Sano Pharmaceuticals 1997; Co-PI’s: Keith Conners, Ph.D. & John March, M.D., M.P.H., Investigator: Kratochvil

CONSULTING POSITIONS State of Nebraska

• Homeland Security Policy Group o Appointed 2020

Editorial

• Pediatric Psychopharmacology: Principles & Practice, 2nd Edition


10

o Oxford Press, 2011 o Martin, Scahill and Kratochvil editors

• Journal of the American Academy of Child & Adolescent Psychiatry o Editorial Board, 2009-2016 o Assistant Editor, 2004-2009 o Reviewer, 2002-Present

• Journal of Attention Disorders o Editorial Board, 2005-2014 o Reviewer, 2006-2014

• Journal of ADHD and Related Disorders o Associate Editor, 2010

• Child and Adolescent Psychiatry and Mental Health o Editorial Board, 2006-2015

• Brown University Child and Adolescent Psychopharmacology Update o Editor, 2007-2010 o Guest Editor, May 2003, Feb 2006, March 2006, May 2006-2007

• Psychiatric Annals o Guest Editor, April 2010

• Pediatric Drugs o Editorial Board, 2006-2016

• American Society of Clinical Psychopharmacology o Co-Editor, Child & Adolescent Section, Model Curriculum on

Psychopharmacology, 2007-2010

• Neuropsychiatry o Editorial Advisory Board, 2010-2014

• Prior Ad Hoc Reviewer o International Clinical Psychopharmacology, Biological Psychiatry, CNS

Spectrums, Journal of Clinical Psychiatry, Pediatrics, Journal of Child & Adolescent Psychopharmacology, Bipolar Disorders - An International Journal of Psychiatry and Neurosciences, Expert Opinion on Drug Delivery, Journal of Child Psychology, Psychiatry, and Allied Disciplines, Drug Benefit Trends, Drug Safety, Expert Review of Neurotherapeutics, Doody Publishing, US Pharmacopeia, Pharmacological Reviews

Food & Drug Administration

• Psychopharmacology Advisory Panel, 2011-Present (appointed through 6/21/19) National Institutes of Health

• IDEA States Pediatric Clinical Trials Network o Nebraska Pediatric Clinical Trials Unit Scientific Oversight Committee, 2015-

Present National Institute of Mental Health

• National Institute of Mental Health Special Emphasis Panel o 2014/01 ZMH1 ERB-D (01)

• National Institute of Allergy and Infectious Diseases o 2013/10 ZAI1 JBS-A (S3) 1 (Clinical Trials Units for NIAID Networks)

• National Institute of Child Health and Human Development o Autism Centers of Excellence (ACE) Centers Review, 2012

• Interventions Committee for Disorders Involving Children and Their Families (ITVC), National Institute of Mental Health Initial Review Group


11

o 2009, 10/5/09 o 2008/10, 6/10/08-6/11/08 o 2008/05, 2/12/08 o 2008/01, 10/10/07-10/11/07 o 2007/10, 6/19/07 o 2007, 2/13/07-2/14/07 o 2007/01, 10/10/06 o 2006/10, 6/20/06

• Child Interventions Panel/Special Emphasis Panel/Initial Review Group o 2008/01 ZMH1 ERB-M 02 S, 10/18/07 (Chair of Panel) o 2007 ZMH1-ERB-D (05), 12/11/06 o 2006/08 ZMH1 ERB-P (07), 2/8/06-2/9/06 o 2006/01 ZMH1 ERB-P (01), 10/24/05-10/25/05 o 2005 ZMH1 ERB-P (07), 6/14/2005-6/15/2005 o 2005/05 ZMH1 ERB-P (05), 2/8/2005-2/9/2005 o 2005/01 ZMH1 ERB-P (02) (S), 10/13/2004-10/14/2004.

• NIMH Loan Repayment Program, Reviewer o ZMH1 ERB-X C1, March 24, 2017 o ZMH1 IRB-I C1, April 4, 2011 o ZMH1 ERB-I C3, March 30, 2009 o ZMH1 ERB-Y March 27, 2007 o ZMHI ERB-G C3 S, March 28, 2006 o ZMH1 ERB-M, May 16, 2005 o ZMH1 DEA-M (C8), May 13-14, 2004 o ZMH1, May, 2003

• Developing & Advance Centers for Intervention and Services Research o ZMH1 ERB-F (01) October 22, 2010

• Data Safety Monitoring Board; 5R01MH070935-04 / 3R01MH070935 Predicting Response to Atomoxetine and Methylphenidate/Methylphenidate and Atomoxetine in ADHD, 2007-2012

• Data Safety Monitoring Board, Chair; Pediatric MDD: Sequential Treatment with Fluoxetine and Relapse Prevention CBT, Data Safety Monitoring Board, 2008-Present R01-MH39188

• Data Safety Monitoring Board; 1R01HD060617-01A1, Reading ICARD: Interventions for Children with Attention and Reading Disorders, 2010-Present

• Management of Excessive Psychotropic Medication for Youth in Out-of-Home Care 1 R13 MH094101-01 NIMH/NICHD 05/01/2011 – 09/30/2011 Invited Expert Participant: Christopher Kratochvil, M.D.

• Data Safety Monitoring Board; ERA Commons ID: Grant 11001651; Imaging Stimulant and Non-Stimulant Treatments for ADHD: A Network-Based Approach, Newcorn & Schulz, 2012-present

• Data Safety Monitoring Board; HRSA UA3MC11054; Treatment of Overweight Induced by Antipsychotic Medication in Young People with ASD, Anagnostou, 2013-Present

National Eye Institute

• Data Safety Monitoring Board: Convergence Insufficiency Treatment Trial: Attention and Reading Trial (CITT-ART). 2014-Present

Department of Defense


12

• Congressionally Directed Medical Research Programs, Neurofibromatosis Research Program Review Panel, August 27, 2013

Johns Hopkins

• Johns Hopkins Biocontainment Unit Scientific Advisory Board, 2016-present Netherlands Organization for Health Research and Development

• Prevention Program, grant review, 2/27/07 Catalan Agency for Health Technology Assessment and Research, Spain

• Grant reviewer, 2009 Clinical

• Samaritan Counseling Center, Omaha, NE; Psychiatric Consultant, 2000-2002

• Nebraska Department of Human Services, Lincoln, NE; Site Inspector & Psychiatric Consultant; 1997-2001

• Boys Town, Psychopharmacology Instruction for Staff Development Nationally, Boys Town, NE; 1997-1999

• Consultant – Lutheran Family Services, Bellevue, NE; Psychiatric Consultant; 1997-1998

Industry

• Data Safety Monitoring Board, Neuren o 2013-2014

• Data Safety Monitoring Board-Mt Sinai, Newcorn Investigator Initiated Trial: Imaging Stimulant and Non-Stimulant Treatments for ADHD: A Network-Based Approach

o 1 pediatric protocol, 2011-2014

• Data Safety Monitoring Board, Pfizer o 4 pediatric protocols, Chair, 2011- 2016 o 4 pediatric protocols, Chair, 2005-2009

• Data Safety Monitoring Board, Otsuka o 3 pediatric protocols, Chair, 2012-2014

• Data Safety Monitoring Board, Seaside o 5 protocols, Chair, 2011-2013

• Data Safety Monitoring Board, AstraZeneca o 2 pediatric protocols, 2004-2007

• Data Safety Monitoring Board, Organon o 3 pediatric protocols, March 2003-2006

• Quintiles- Consultant 2010—2014 • Theravance Advisor 2010-2012

• AstraZeneca, ADHD Advisory Board, 2009

• Abbott, National Advisory Board, 2007-2008

• National Alliance for the Advancement of ADHD Care, National Advisory Board, June 2002-2003

• Eli Lilly & Company, Global ADHD Advisory Board, 2002-2007

• Eli Lilly & Company, National ADHD Advisory Board, 2001-2005

• Boehringer Ingelheim, Consultant, 2005

• Cephalon, ADHD Executive Advisory Board, 2005-2006

• Shire Pharmaceuticals, ADHD Advisory Board, 2002, 2005


13

Nebraska Data Advisory Board

• Joint Public Health Data Center Advisory Board, 2012-2014 UNeMed

• Biomedical Innovation Accelerator Steering Committee, 2014-2015 CME

• Primary Pediatric Psychopharmacology Steering Committee (PPP-SC), in collaboration with the REACH Institute (The Resource for Advancing Children’s Health) 2006-2012

• CME Outfitters, Professional Advisory Board, 2006-2007

• Massachusetts General Hospital Psychiatry Academy, Affiliate Faculty, 2005-2006 HONORS AND AWARDS

• Nebraska Admiral, honored by the Governor of Nebraska as an Admiral in the Great Navy of the State of Nebraska for service to the State 2015

• Honored along with the Nebraska Biocontainment Patient Care Unit in Resolution, University of Nebraska Board of Regents 2015

• Honored along with the Nebraska Biocontainment Patient Care Unit in Legislative Resolution 41, 104th Legislature of Nebraska 2015

• Midlanders of the Year, Nebraska Medicine Ebola Team, Omaha World-Herald Newspaper 2015

• The 2015 Distinguished Service Award, The Nebraska Infection Control Network 2015 • Anna O. Stake Professor of Child Psychiatry, UNMC, 2014-Present

• Best Doctors in America, 2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014, 2015-2016, 2017-2018

• Distinguished Fellow, American Psychiatric Association, 2015-Present

• Fellow of the American Academy of Child & Adolescent Psychiatry, 2010-Present

• Fellow of the American Psychiatric Association, 2009-2014

• Distinguished Scientist, University of Nebraska Medical Center, 2008

• Klingenstein Third Generation Foundation Award for Research in Depression or Suicide, awarded by the American Academy of Child & Adolescent Psychiatry to the Treatment for Adolescents with Depression (TADS) Team, 2007

• Visiting Professor; University of Ulm; Ulm, Germany June, 2007 • AACAP Outstanding Mentor Award, 2005

• Chancellor’s Silver “U” Award, 2003

• Assembly William Sorum Award, American Psychiatric Association, 1995

• Outstanding Service Award, Nebraska Psychiatric Association, 1995

• Cecil Wittson Award for Outstanding Resident, Creighton-Nebraska Department of Psychiatry, 1994

Professional Organizations: Nebraska Fulbright Chapter: Board of Directors 2019-Present BioNebraska Life Sciences Organization: Board of Directors 2011-Present Professional Societies: American Academy of Child & Adolescent Psychiatry: Member 1995- Present Member of Council (National Board of Directors)


14

▪ October, 2007-October 2010 National Committees

• Development Committee, Co-Chair, 2011-2013 • Telemedicine Committee, 2002-2004

• Pediatric Psychopharmacology Initiative, 2001-Present o Chair, 2006-2010 o Ethics Subcommittee, 2003-2005

• Work Group on Research, 2001- 2012 o Executive Committee, 2003-2007

• Early Investigators Group, Co-Chair annual meeting, 2004 American Psychiatric Association: Member 1993- Present National Committees

• Council on Children, Adolescents and Their Families, Member, 2009-2011, 2013-2016

• Vice-Chair, 2009-2011

• Council on Research, Consultant 2007-2009

• Council on Children, Adolescents and Their Families, Consultant 2008-2009

• Joint Commission on Public Affairs, 1994-1995 Regional Committees

• Area IV Council, 1994-1995 American Society of Clinical Psychopharmacology: Member 2007-Present American Medical Association: Member 2000-Present Nebraska Council of Child & Adolescent Psychiatry: Member 1997-Present Offices

• President, 2005-2007

• President, 2000-2002

• Secretary/Treasurer, 1998-2000 Nebraska Psychiatric Society: Member 1997-Present Offices

• Executive Committee, Early Career Psychiatrist Representative, 1997-2000 • Program Committee, 1997-1999

• Executive Committee, Member in Training Representative, 1994- 1995 Nebraska Medical Association: Member 1999-2011; 2013-Present Offices

• Commission on Legislative and Government Affairs, 2001-2003 Metro Omaha Medical Society: Member 1999-2009; 2013-Present North Carolina Council of Child & Adolescent Psychiatry: Member 1995-1997 Offices

• Executive Council, 1996-1997 COMMITTEE ASSIGNMENTS University of Nebraska Committees

• NeSIS Executive Advisory Committee o Member, 2012-Present

University of Nebraska Medical Center/Children’s Hospital

▪ Joint Pediatric Institutional Review Board

• Consultant, 2010-Present


15

• Vice Chair, 2009-2010 University of Nebraska Medical Center Committees:

• Clinical Research Center o Advisory Committee Chair, 2010-2012

• Institutional Review Board #2 o Consultant 2010-Present o Vice Chair, 2002-2010 o Member, 2002-2010

• Institutional Review Board #1 o Consultant 2010-Present o Vice Chair, 2002-2010 o Member, 2002-2010

• Research Enterprise Committee, Member, 2003-2006

• Clinical Investigation Advisory Board, Member, 2002-2006

• Ittner and Seed Grant Reviewer, 2002-2003

• Developmental Neuroscience Research Group, Member, 1999-2000 UNMC Department of Psychiatry

▪ Promotion & Tenure Committee, 2010-Present Clinical Enterprise

• Clinical Enterprise Transformation Steering Committee, 2014-Present

• Clinical Enterprise Charitable Contributions Committee (CECC), 2014-Present State of Nebraska

• Joint Public Health Data Center Advisory Board; 2012-Present

• Nebraska State Behavioral Health Emergency Response Team (B-HERT); 2009-2010

• Children’s Mental Health and Substance Abuse State Infrastructure Grant o Steering Committee, 2005-2009 o Academic Committee, 2005-2009

• Behavioral Health Reform Project, Academic Support Subgroup, 2004-2005

• Center of Excellence White Paper Committee for Governor Johanns, 2003 Nebraska Area Health Education Centers

• Fund Advisory Committee, 2007-2008 Creighton University

• Faculty Council, Member, 1998-1999

• Academic Council, Member, 1998-1999 • Compliance Committee, 1998

University of Nebraska Department of Psychiatry

• Psychiatry Symposium Committee, Member, 2001-2006 • Department of Psychiatry Research Development Committee, Member, 2001-2004

• Space Committee, Member, 1999-2001 Creighton-Nebraska Psychiatry Residency Training Program

• Child & Adolescent Residency Training Committee, Member, 1997-2000, 2006-2010 • Child & Adolescent Residency Curriculum Development Committee, 1998-1999

National/International Symposia Chaired “Update on Pediatric Psychopharmacology”, Masters Course Session Chair, 169th Annual

American Psychiatric Association Meeting, Atlanta, GA, May, 2016


16

“Update on Pediatric Psychopharmacology”, Masters Course Session Chair, 168th Annual American Psychiatric Association Meeting, Toronto, CA, May, 2015

“Update on Pediatric Psychopharmacology”, Masters Course Session Chair, 167th Annual American Psychiatric Association Meeting, NY, NY, May, 2014

“Update on Pediatric Psychopharmacology”, Masters Course Session Chair, 166th Annual American Psychiatric Association Meeting, San Francisco, CA, May 18, 2013

“Research and Analytics Council”, Co-Chair, Epic Spring Advisory Council, Verona, WI, April 23-24, 2013

“Update on Pediatric Psychopharmacology”, Masters Course Session Chair, 165th Annual American Psychiatric Association Meeting, Philadelphia, PA, May 8, 2012

“Update on Pediatric Psychopharmacology”, Masters Course Session Chair, 164th Annual American Psychiatric Association Meeting, Honolulu, HI, May 14, 2011

“Perspectives on Current Psychiatric Psychopharmacology Research Needs”, Research Forum, 57th Annual Meeting of the AACAP, New York, NY October 26-31, 2010

“Update on Pediatric Psychopharmacology”, Masters Course Session Chair, 163rd Annual American Psychiatric Association Meeting, New Orleans, LA, May 22, 2010

“Update on Treatment of ADHD in Adults”, Plenary Session Chair, 2nd International Congress on ADHD, Vienna, Austria, May 21-24, 2009

“Practical Pediatric Psychopharmacology”, Symposia Co-Chair, Annual Meeting of the AACAP, Chicago, IL, October 28-Nov 2, 2008

“Advanced Psychopharmacology Institute: Translating Recent Psychopharmacological Research Findings into Clinical Practice”, Symposia Co-Chair, Annual Meeting of the AACAP, Chicago, IL, October 28-Nov 2, 2008

“Ethics Applications in Child & Adolescent Psychopharmacology Clinical Research and Practice”, Symposia Chair, New Clinical Drug Evaluation Unit, Phoenix, Arizona, May 29, 2008

“Practical Pediatric Psychopharmacology”, Symposia Chair, Annual Meeting of the APA, Washington DC, May 2008

“Practical Pediatric Psychopharmacology for the Primary Care Clinician”, Symposia Chair, Annual Meeting of the AACAP, Boston, MA, October, 2007

“Comorbidity and Co-Medication in Children with ADHD and Other Child Psychiatric Disorder. A US American and Central European Perspective”, Co-Chair, 1st International Congress on ADHD, Wurzburg, Germany, June 2-5, 2007

“Treatment of ADHD in Adults”, Co-Chair, 1st International Congress on ADHD, Wurzburg, Germany, June 2-5, 2007

“Practical Pediatric Psychopharmacology for the Primary Care Clinician”, Symposia Chair, Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006

“Advocating for Change Through Evidence-Based Medicine: A Focus on ADHD”, Sympsium Chair, Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 21-24, 2006.

“Clinical Perspectives on ADHD with Comorbidities”, Symposium Chair. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.

“Research Literacy: Speeding the Adoption of Evidence-Based Medicine (EBM) in Pediatric Psychiatry“, Co-Chair of Research Forum. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.

Placebo and Alternatives to Placebo in Randomized, Controlled Trials in Pediatric Psychopharmacology.” Co-Chair of Research Forum. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, San Francisco, CA, October 22-23, 2002.

“New Approaches for Treating ADHD: The Whole Life Perspective.” Symposium Chair. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18-23, 2002.


17

“Pharmacotherapies in Young Children with ADHD.” Symposium Chair. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18-23, 2002.

National/International Presentations “The Role of Academic Health Centers in Readiness”. The 2019 Annual Meeting of the Association of Academic Health Centers, Miami, FL. Sep 26-27, 2019. “The Global Center for Health Security: A Model of Global Preparedness for Emerging

Infectious Diseases”, XV Congress of the Spanish Society of Virology / 11th International Meeting GVN, June 2019, Barcelona, Spain

“Ebola and the Rapid Research Paradigm”, NCCN Institutional Review Board Directors Forum, Fred and Pamela Buffett Cancer Center, October 2018 Omaha, Ne

“The Nebraska Biocontainment Unit: A National Resource, A Decade in the Making”, Seoul, South Korea, July, 2016

“Experimental Therapeutics” 2015 Annual Symposium of the China-US Research Center for Life Sciences Infectious Diseases and Control, Beijing, China October, 2015

“Ebola: Be Afraid but not That Afraid” The Nebraska Experience. 168th Annual American Psychiatric Association Meeting, Toronto, CA, May, 2015

“Pharmacotherapy for Children and Adolescents with ADHD”, Masters Course Session, 167th Annual American Psychiatric Association Meeting, NY, NY, May, 2014

“Pharmacotherapy for Children and Adolescents with ADHD”, Masters Course Session, 166th Annual American Psychiatric Association Meeting, San Francisco, CA, May 18, 2013

“Capacity to Consent”, MAGI’s Clinical Research Conference 2013, Boston, MA, May 7, 2013 “Academic Health Centers and Research Implementation”, Epic Spring Advisory Councils and

Forums, Verona, WI April23, 2013 “Clinical Lessons Learned from NIMH-Funded Pediatric Multi-Site Trials”, Tulane University,

New Orleans LA, December 8, 2012 “ADHD, Irritability, and Pediatric Bipolar Disorder”, Massachusetts General Hospital 2012

Pediatric Bipolar Disorder Conference, Boston, MA, March 30, 2012. “Negotiating Successful Partnerships”, 2011 Joint Executive Leadership Group Meeting,

Association of Academic Health Centers, Washington, DC, December 2011 “Management of Pediatric Depression in a Primary Care Setting”, 58th Annual Meeting of the

AACAP, Toronto, ON, Canada, October 22, 2011 “Pediatric Psychopharmacology and Depression in Children & Adolescents”, 2011 Sino-

American Symposium on Clinical and Translational Medicine, Shanghai China, June 24-26, 2011

“Pharmacotherapy for Children & Adolescents with ADHD”, 164th Annual American Psychiatric Association Meeting, Honolulu, HI, May 14, 2011

“ADHD Pharmacotherapy Update”, 15th Annual Psychiatric Update, University of Texas Medical Branch, Galveston, TX April 1, 2011

“Stimulant Research: Strengths, Limitations, and Potential Targets”, 57th Annual Meeting of the AACAP, New York, NY October 26-31, 2010

“Management of Pediatric Depression in a Primary Care Setting”, 57th Annual Meeting of the AACAP, New York, NY October 26-31, 2010

“Pharmacotherapy for Children & Adolescents with ADHD”, 163rd Annual American Psychiatric Association Meeting, New Orleans, LA, May 22, 2010

“Psychopharmacology: Practical Pediatric Management from Toddlers to Teens”, Annual Meeting of the American Academy of Pediatrics, Washington, DC, October 17-20, 2009

“Interventions and Psychopharmacology for the Primary Care Physician and the Developmental-Behavioral Specialist”, Annual Meeting of the American Academy of Pediatrics, Washington, DC, October 17-20, 2009


18

“Psychostimulant Treatment and Problems in Daily Care”, 2nd International Congress on ADHD, Vienna, Austria, May 21-24, 2009

“Update on Treatment of ADHD in Adults”, 2nd International Congress on ADHD, Vienna, Austria, May 21-24, 2009

“Depression in Children and Adolescents: Relevance of Recent Research to Clinical Practice”, University of Utah Kevin Finnegan, M.D. Memorial Grand Rounds, 2009

“Depression in Children and Adolescents: Relevance of Recent Research to Clinical Practice”, Yale Child Study Center, New Haven, CT, February 2009

““Principles of Psychopharmacology”, DB:PREP Intensive Review of Behavioral Pediatrics, Atlanta, GA, December 4-7, 2008

“Mood Disorders: Evaluation, Management and Treatment”, DB:PREP Intensive Review of Behavioral Pediatrics, Atlanta, GA, December 4-7, 2008

“A Double-Blind, Placebo-Controlled Study of Atomoxetine in Young Children with ADHD”, Annual Meeting of the AACAP, Chicago, IL, October 28-Nov 2, 2008

“Pharmacological Challenges in the Treatment of ADHD with Comorbidity”, Annual Meeting of the AACAP, Chicago, IL, October 28-Nov 2, 2008

“Depression in Children and Adolescents: Relevance of Recent Research to Clinical Practice”, 22nd Annual Biologic Basis of Pediatric Practice Symposium, Deer Valley Utah, September 7, 2008

“Consensus Building to Generate Conflict of Interest Guidelines for Practitioners”, New Clinical Drug Evaluation Unit, Phoenix, Arizona, May 29, 2008

“Minimizing Growth Effects of ADHD Medication in Clinical Practice”, APA Annual Meeting, Washington DC, May 9, 2008

“Pediatric Psychopharmacology Case Discussions”, APA Annual Meeting, Washington DC, May 4, 2008

“Pediatric Psychopharmacology,“ NICHQ - Reaching Children Initiative Learning Collaborative, NY, NY, September 25, 2007

The Treatment for Adolescents with Depression Study (TADS): Implications for Practice,” Children’s Hospital Medical Center, Cincinnati, Ohio, September 12, 2007

“The Treatment for Adolescents with Depression Study (TADS): Implications for Practice,” University of Cincinnati, Cincinnati, Ohio, September 12, 2007

“Evidence-based Treatment of ADHD”, University of Ulm, Ulm, Germany. June 6, 2007 “Psychopharmacological Indications and Approaches”, 1st International Congress on ADHD,

Wurzburg, Germany, June 2-5, 2007 “Modafinil”, 1st International Congress on ADHD, Wurzburg, Germany, June 2-5, 2007 “Minimizing Growth Effects of ADHD Medication in Clinical Practice”, 47th Annual Meeting of the

New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 14, 2007 “ADHD: Diagnostic Dilemmas & Controversies”, Annual Meeting of the American Psychiatric

Association, San Diego California, May 23, 2007 “Addressing Treatment of Special Groups: Preschool Children and Adults”, Annual Meeting of

the American Psychiatric Association, San Diego, California, May 23, 2007 “Comparison of Major Depressive Disorder and its Treatment in Children and Adults”,

Experimental Biology 2007, Washington DC, April 28-May 2, 2007 “Psychopharmacology in the Treatment for Adolescents with Depression Study (TADS)”, grand

rounds, University of Texas San Antonio, March 27, 2007 “ADHD Pharmacotherapy for Adolescents and Adults”, Improving Long-term Outcomes in

ADHD: A Treatment Development Workshop, NIMH, Bethesda, MD, March 12-13, 2007 “ADHD: An Office-Based Dilemma”, Annual Clinical Advances in Pediatrics Meeting, Children’s

Mercy Health Network, Kansas City, MO, November 16, 2006 “Research and Academic Psychiatry: The View from Nebraska”, Annual Meeting of the AACAP,

San Diego, CA, October 24-29, 2006


19

“Pharmacotherapy for Young Children with ADHD”, Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006

“Psychopharmacology of ADHD in an Era of Regulatory Concern”, Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006

“Adolescent Depression: Innovations in Evidence-Based Treatment”, The Mental Health Association of Franklin County & Ohio State University, Columbus Ohio, October 3, 2006

“Update on the Pharmacological Management of ADHD in Children and Adolescents”, 9th Annual Clinical Pediatric Psychopharmacology State of the Art: Practical, sponsored by Albert Einstein College of Medicine & Montefiore Medical Center, New York, NY, September 15, 2006

“Phenomenology and Diagnosis of ADHD”, Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 23, 2006

“Treatment Effects on Remission Rates, Level of Functioning, Overall Health, and Quality of Life”, Annual Meeting of the Society of Biological Psychiatry, Toronto, Canada, May 19, 2006

“Treatment for Adolescent Depression: FDA Hearings, Research Findings and Clinical Implications”, Psychiatry Grand Rounds, University of Utah, Salt Lake City, Utah, January 4, 2006.

“A Research Career in Nebraska: Risks and Rewards”, NIH New Investigator Session, Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.

“Medications for ADHD”, Annual Meeting of the American Academy of Pediatrics, Washington, D.C., October 8-11, 2005.

“Pharmacotherapy for ADD/ADHD”, Psychopharmacology Update 2005, sponsored by Baylor College of Medicine & South Central VA MIRECC, Houston, Texas, October 15, 2005.

“ADHD Symptoms and Behavior Improved with Modafinil Pediatric Formulation”, Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 23, 2005.

“The Course of ADHD from Adolescence into Adulthood”, Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 24, 2005.

“Large Observational Studies of ADHD: Methodology and Results”, Symposium Discussant, Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 24, 2005.

“Pediatric Depression: Clinical Issues, Controversies and Current Research”, 9th Annual Practical Use of Psychiatric Medications, Billings, Montana, April 29, 2005

“Pharmacotherapy of ADHD in Children & Adolescents”, Ste-Justine Hospital, Montreal, Canada, April 7, 2005

“Pharmacotherapy of ADHD in Children & Adolescents”, Hetel Dieu Hospital, Kinston, Ontario, Canada, April 6, 2005

“Nonstimulant Treatments: Overview of Acute and Long-term Efficacy”, 2004 Latin America Regional Medical Conference, Buenos Aires Argentina, November 11-12, 2004.

“The Role of Atomoxetine in the Treatment of ADHD”, XXIVth Collegium Internationale Neuro-Psychopharmacologicum, Paris, France, June 19-25, 2004.

“Overview of Nonstimulant Treatments for ADHD”, Warren Wright Lecture, Northwestern University, Chicago, IL, April 23, 2004.

“Update on ADHD.” 7th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Chicago, IL, April 22-25, 2004.

“Update on the Treatment of ADHD”. Duke University Medical Center, Division of Child & Adolescent Psychiatry, Durham, NC, March 24th, 2004.

“Update on ADHD: Is the Treatment of ADHD a ‘Done Deal’ or is There Still Need for Improvement?” AACAP 2004 Psychopharmacology Update Institute, New York, NY, January 16-17, 2004.

“Presentation of the Treatment of a Child Using a New, Long-duration Medication”. AACAP 2004 Psychopharmacology Update Institute, New York, NY, January 16-17, 2004.


20

“New Pharmacological Treatments in ADHD”, 1st International Congress in ADHD, Asociacion Mexicana por el deficit de atencion, hiperactividad y Trastornos asociados A.C., Mexico City, Mexico, November 15, 2003.

“New and Emerging Pharmacotherapies in ADHD”, Annual Meeting of the IG-ADHD, Koblenz, Germany, November 8, 2003.

“Optimizing Symptom Relief in Patients with ADHD: Treatment and Effects”. Symposium presented at the Annual meeting of the American Academy of Pediatrics, New Orleans, LA, November 4, 2003.

“Treatment for Adolescents with Depression Study (TADS)”. March JS, Emslie GJ, Curry JF, Kratochvil CK, Silva S. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.

“Assessment of Safety in Child Mental Health Research: Obstacles and Opportunities”, Symposium Rapporteur. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.

“Non-stimulant Treatment of ADHD”, Columbia University and New York State Psychiatric Institute Grand Rounds, New York, NY, October 8, 2003.

“New Directions in the Treatment of ADHD”, Henry Ford Hospital Grand Rounds, Detroit, Michigan, September 25, 2003.

“New ADHD Treatment Options”, New York University Child Study Center Grand Rounds, New York, NY, September 19, 2003.

“New Developments in the Pharmacotherapy of Children & Adolescent ADHD”, at Wayne State University Symposium “New Advances in the Assessment and Treatment of ADHD Across the Lifespan”, Detroit, MI, September 13, 2003.

“Pharmacotherapy of Young Children and Adults with ADHD” at Wayne State University Symposium “New Advances in the Assessment and Treatment of ADHD Across the Lifespan”, Detroit, MI, September 13, 2003.

“New and Emerging Pharmacotherapies for ADHD”, University of Texas Health Science Center at San Antonio, San Antonio, Texas, September 2, 2003.

“New ADHD Treatment Options in Adults”, University of Cincinnati Grand Rounds, Cincinnati, OH, May 14, 2003

“New ADHD Treatment Options”, Cincinnati Children’s Hospital Grand Rounds, Cincinnati, OH, May 14, 2003

“A Randomized, Placebo-Controlled Study of Once-Daily Atomoxetine in the School Setting in Children with ADHD”, Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 20, 2003.

“Treatment of ADHD with Nonstimulants”, 1st Annual Child and Adolescent Psychiatry: The Place for Pharmacotherapy and Psychotherapy, Washington, DC, April 4-5, 2003.

“New ADHD Treatment Options, 8th Annual Psychopharmacology Research Conference,” Sponsored by the Nevada Psychiatric Association and American Psychiatric Association, Las Vegas, Nevada, February 13, 2003.

“Pharmacotherapeutic Research in Pediatric ADHD,” Children’s Hospital of Michigan & Wayne State University Grand Rounds, Detroit, MI, February 11, 2002.

“An Introduction to the Children’s Regulations and IRB Issues Pertinent to Pediatric Research.” Annual Meeting of Public Responsibility in Medicine and Research, San Diego, CA, November 18, 2002.

“Update on Atomoxetine: A New Nonstimulant for ADHD.” Annual Meeting of the American Association of Child & Adolescent Psychiatry, San Francisco, CA, October 25, 2002.

“Can Newer Agents and Formulations Improve Outcomes in Patients with ADHD?” Annual Meeting of the American Association of Pediatrics, Boston, MA, October 21, 2002.

“The Recognition and Treatment of Childhood Depression, at Depression: Management Across the Lifecycle, Sponsored by the Medical University of South Carolina, Charleston, SC, October 12, 2002.”


21

“New and Emerging Pharmacotherapies for ADHD, at Pharmacology of ADHD in the 21st Century: A Window into the Future”, Sponsored by the National Association for Continuing Education, Toronto, Ontario, October, 4, 2002.

“New ADHD Treatment Options on the Horizon.” 155th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18, 2002.

“Principal Investigator’s Challenge.” AACAP Research Forum, 48th Annual American Academy of Child & Adolescent Psychiatry Meeting, Honolulu, HI, October 25, 2001.

“Atomoxetine: A new Non-Dopaminergic Intervention for ADHD.” 48th Annual American Academy of Child & Adolescent Psychiatry Meeting, Honolulu, HI, October 23-28, 2001.

“Expanding Treatment Options for ADHD: New Alternatives.” Annual Meeting of the American Academy of Pediatrics, San Francisco, CA, October 21, 2001.

“Treatment Research in Child and Adolescents from Design to Implementation of Clinical Trials Workshop: Successful Recruitment Strategies in Multi-Site Trials.” 41st Annual NCDEU Meeting, Phoenix, AZ, May 28, 2001.

“Challenges and Opportunities in Recruiting Participants for NIMH Multi-Center Clinical Trials: Current Experiences for the Field Studies in Children.” 41st Annual NCDEU Meeting, Phoenix, AZ, May 28, 2001.

“Evidence for genetic determinants of ADHD.” Scientific Proceedings of the 56th Annual Society of Biological Psychiatry Meeting, New Orleans, LA, May 3, 2001.

“Human research issues involving people with mental illness, dementia, or cognitive impairment.” 11th World Congress of the International Association for the Scientific Study of Intellectual Disabilities, Seattle WA, August 1, 2000.

“Psychiatry Residents as Active Researchers: The Experiences of Two Programs” American Association of Directors of Psychiatry Residency Training, Charleston, SC, 1997

Regional Symposia Chaired

“Child and Adolescent Mental Health Conference”, sponsored by UNMC Department of Psychiatry, Omaha, NE, September 23, 2005

“ADHD across the Ages: Preschool to Adulthood”, conference sponsored by UNMC Department of Psychiatry, Omaha, NE, September 26, 2003.

Regional Presentations

“New Directions in Oncology Clinical Trials: Creating the Future in Treatment”, The Seventh: Extraordinary Innovations and Emerging Trends in Transplantation and Oncology from Nebraska Medicine Conference, Omaha, NE, July 2016

“From West Africa to Omaha: Research on Ebola and other Emerging Pathogens”, Human Subjects Conference, Omaha, NE, September 2015

“What’s New in Treatment and Diagnosis ADHD”, 2015 Primary Care Conference, Bryan Health Lincoln, NE, May 2015

“ADHD- A Discussion of Definition, Etiology, Presentation & Management”, UNMC Munroe-Meyer Institute Symposium 2012, Omaha, NE June 2012

“Child & Adolescent Mental Health Issues”, 41st Family Medicine Review Course, UNMC, Omaha, NE, April 2012

“Child & Adolescent Mental Health Issues”, 40th Family Medicine Review Course, UNMC, Omaha, NE, April 2011

“Child & Adolescent Mental Health Issues”, 38th Family Medicine Review Course, UNMC, Omaha, NE, April 2009

“Depression in Children and Adolescents: Relevance of Recent Research to Clinical Practice”, Children’s Hospital, Omaha, Nebraska, September 2008


22

“Update on ADHD”, University of South Dakota, Sioux Falls, SD, April 18, 2008 “Update on ADHD Pharmacotherapy”, Nebraska Pharmacists Association Annual Convention,

Lincoln, NE, July 20, 2007 “Treatment for Adolescent Depression: FDA Hearings, Research Findings and Clinical

Implications”, Children’s Hospital, Omaha, NE, February 3, 2006 “Attention Deficit Hyperactivity Disorder”, Child & Adolescent Mental Health Conference

sponsored by UNMC Department of Psychiatry, Omaha, NE September 23, 2005 “Child and Adolescent Depression”, UNMC Department of Family Practice Grand Rounds,

Omaha, NE; May 11, 2005 “Pediatric Depression”, 8th Annual Practical Pediatrics: 2005 Update, Omaha, NE, February 18,

2005 “Pediatric Depression: Clinical Issues, Controversies and Current Research”, UNMC

Department of Psychiatry Grand Rounds, Omaha, NE; January 27, 2005 “Update on Pediatric Depression”, Nebraska Psychological Association 2004 Fall Conference;

Omaha, NE, October 1, 2004. “Current Perspectives in Pediatric Psychopharmacology”, 10th Annual Midwest

Neuropsychopharmacology Update; Kansas City, MO, September 10, 2004. “Update on New and Emerging Pharmacotherapies for ADHD”, Annual Meeting of the Nebraska

Pharmacists Association, Kearney, NE, July 30, 2004. “Attention-Deficit/Hyperactivity Disorder”, 7th Annual Practical Pediatrics: 2004 Update; Omaha,

NE, February 20, 2004. “Biological Aspects of ADHD”, Grand Rounds, Department of Psychiatry, University of Nebraska

Medical Center, Omaha, NE, January 28, 2004. “Pharmacotherapy for ADHD”, ADHD across the Ages: Preschool to Adulthood Symposium,

Conference sponsored by UNMC Department of Psychiatry, Omaha, NE, September 26, 2003.

“Biological Aspects of ADHD”, John A. Wiebe, Jr. Research Lecture Series, Children’s Hospital, Omaha, NE, September 12, 2003

“New Treatments for ADHD”, Nebraska Chapter of the American Academy of Pediatrics, Children’s Hospital, Omaha, NE, April 11, 2003

“ADHD in Children and Adolescents”, Mary Lanning Department of Pediatrics Grand Rounds; Hastings, NE, September 28, 2002

“Attention Deficit Hyperactivity Disorder and Depression”, UNMC Symposium on Treating Depression in the Complex Patient, Omaha, NE, April 5, 2002

“ADHD Diagnosis and Treatment in Children, Adolescents and Adults”; University of Nebraska Medical Center, Department of Psychiatry, Grand Rounds, Omaha, NE, November 7, 2001.

“Child and Adolescent Depression”, Practical Pediatrics, 2001, Creighton University and Children’s Hospital, Omaha, NE, February 16, 2001.

“Treatment of ADHD: An Overview”, UNMC Department of Pharmacology, Omaha, NE, November 17, 2000

“ADHD Linking Basic Science and Clinical Research”; Cell Biology and Anatomy Seminar Series; UNMC, Omaha, NE, August 29, 2000

“ADHD in Children & Adolescents”, Richard Young Center Family Practitioner Psychiatric Update, Omaha, NE, July 28, 2000.

“Major Depression in Children and Adolescents”, Mary Lanning Department of Pediatrics Grand Rounds; Hastings, NE, April, 2000

“Attention Deficit Hyperactivity Disorder”, Children’s Hospital Grand Rounds; Omaha, NE, March 24, 2000

“Treatment of Adolescent Depression Study”, Nebraska Department of Psychiatry Grand Rounds; Omaha, NE, March 8, 2000

“Attention Deficit Hyperactivity Disorder Practical Pediatrics: 2000 Update”, Creighton University and Children’s Hospital, Omaha, NE, February 18, 2000


23

“OCD in Children and Adolescents”, Creighton-Nebraska Department of Psychiatry Grand Rounds, Omaha, NE 1999

“Risk Taking Behaviors of Youth” Symposium Entitled “Gangs, Drugs & Violence” Saint Joseph Hospital, Omaha, NE 1998

“Psychopharmacology of Child and Adolescent Anxiety Disorders”, Creighton-Nebraska Department of Psychiatry Grand Rounds, Omaha, NE 1998

“Pediatric Psychopharmacology” Monthly Seminar, Boys Town National Research Institute Omaha, NE 1997 to 1998

“Psychopharmacology in School-aged Children”, Fayetteville Area Health Education Center Workshop, Fayetteville, NC 1997

“Externalizing Disorders” Children’s Psychiatric Institute Conference, Chapel Hill, NC, 1996 COMMUNITY SERVICE

• Creighton University Parents Advisory Board o Co-chair 2018-present o Member 2017-present

• Building Healthy Futures o Evaluation Advisory Council, 2015-2016 o School-Based Health Center Advisory Board, 2013-2016 o Oral Health School Based Services Program, Evaluation Advisory Group,

2014-2016

• Building Bright Futures o School-Based Health Center Advisory Board, 2010-2013 o Chair, Behavioral/Mental Health Subcommittee 2011-2013

• St. Margaret Mary, Parish Council, 2009-2011

• St. Margaret Mary School, School Board, 2005-2008

• Medical Reserve Corp, 2005-2006

• Cub Scouts, Den Leader, 2001-2005

• Catholic Youth Soccer League, Coach, 2000-2008

• Children & Adults with Attention Deficit Hyperactivity Disorder (CHADD), Omaha, NE; Professional Advisory Board; 1999-2006

Articles Published in Scholarly Journals

1. Beam, E.L., Schwedhelm, M.M., Boulter, K.C., Vasa, A.M., Larson, L., Cieslak, T.J., Lowe, J.J., Herstein, J.J., Kratochvil, C.J., &Hewlett, A.L., (2019) Ebola Virus Disease: Clinical Challenges, recognition, and management. Nursing Clinics of North America, in press. https://doi.org/10.1016/j.cnur.2019.02.001

2. Vasa, A., Madad, S., Larson, L., Kraft, C., Vanairsdale, S., Grein, J., Garland, J., Butterworth, V., & Kratochvil, C. (2018). A Novel Approach to Infectious Disease Preparedness: Incorporating Investigational Therapeutics and Research Objectives into Full Scale Exercises. Health Security, 2018

3. Kortepeter MG, Cieslak TJ, Kwon EH, Smith PW, Kratochvil CJ, Hewlett AL, Comment on “Ebola virus infection among western healthcare workers unable to recall the transmission route.” [Letter} Biomed Research internet epub Sept 2017..

4. Kratochvil CJ, Evans L, Ribner BS, Lowe JJ, Harvey MC, Hunt RC, Tumpey AJ, Fagan RP, Schwedhelm MM, Bell S, Maher J, Kraft CS, Cagliuso NV Sr, Vanairsdale S, Vasa A, Smith PW. The National Ebola Training and Education Center: Preparing the United


24

States for Ebola and Other Special Pathogens. Health Secur. 2017 May/Jun;15(3):253-260

5. Vasa A, Smith PW, Schwedhelm M, Cieslak TJ, Lowe J, Kratochvil CJ, Beam EL, Boulter K, Hewlett A. (2017) Advancing Preparedness for Highly Hazardous Contagious Diseases: Admitting 10 Simulated Patients with MERS-CoV. Health Security.15(4):432-439. PMID:28805464.

6. Kortepeter MG, Cieslak TJ, Kwon EH, Smith PW, Kratochvil CJ, Hewlett AL. (2017) Comment on "Ebola Virus Infection among Western Healthcare Workers Unable to Recall the Transmission Route". Biomed Research International. PMID: 29085841

7. Beam EL, Schwedhelm S, Boulter K, Kratochvil C, Lowe J, Hewlett A, Gibbs SG, Smith PW. Personal protective equipment processes and rationale for the Nebraska Biocontainment Unit during the 2014 activations for Ebola virus disease. Am J Infect Control. 2015 Nov 7.

8. Jelden Kately, Smith Philip, Schwedhelm Michelle, Gibbs Shawn, Lowe John, Beam Elizabeth, Kratochvil Christopher, Boulter Kathleen, BAN (HONS), Hewlett Angela. Learning from Ebola: Interprofessional practice in the Nebraska Biocontainment Unit. Journal of Interprofessional Education & Practice

9. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon GM 3rd, Friedman-Moraco RJ, Marconi VC, Hill CE, Sullivan JN, Johnson DW, Lisco SJ, Mulligan MJ, Uyeki TM, McElroy AK, Sealy T, Campbell S, Spiropoulou C, Ströher U, Crozier I, Sacra R, Connor MJ Jr, Sueblinvong V, Franch HA, Smith PW, Ribner BS; Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit. The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. Clin Infect Dis. 2015 Apr 22. pii: civ334.

10. Iwen PC, Smith PW, Hewlett AL, Kratochvil CJ, Lisco SJ, Sullivan JN, Gibbs SG, Lowe JJ, Fey PD, Herrera VL, Sambol AR, Wisecarver JL, Hinrichs SH. Safety considerations in the laboratory testing of specimens suspected or known to contain Ebola virus. Am J Clin Pathol. 2015 Jan;143(1):4-5.

11. Lowe JJ, Olinger PL, Gibbs SG, Rengarajan K, Beam EL, Boulter KC, Schwedhelm MM, Hayes AK, Kratochvil CJ, Vanairsdale S, Frislie B, Lewis J, Hewlett AL, Smith PW, Gartland B, Ribner BS. Environmental Infection Control Considerations for Ebola. American Journal of Infection Control. 2015 Jul 1;43(7):747-9.

12. Smith, P.W., Boutler, K.C., Hewlett, A.L., Kratochvil, C.J., Beam, E., Gibbs, S.G., Lowe, J.J., Schwedhelm, S.S. Planning and Response to Ebola virus disease: An Integrated Approach. American Journal of Infection Control. 2015; 43(5):441-446.

13. Jelden K.C., Gibbs S.G., Smith P.W., Schwedhelm S., Iwen P.C., Beam E., Hayes K.A, Marion N., Kratochvil C.J., Boulter K.C., Hewlett A.L., Lowe J.J. Nebraska Biocontainment Unit Patient Discharge and Environmental Decontamination Following Ebola Care American Journal of Infection Control. 2015; 43:203-5.

14. Upadhyaya H, Kratochvil C, Ghuman J, Camporeale A, Lipsius S, D'Souza D, Tanaka Y. Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2014 Sep 29.

15. Lin DY, Kratochvil CJ, Xu W, Jin L, D’Souza DN, Kielbasa W, Allen AJ, (2014). A Randomized Trial of Edivoxetine in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder, J of Child and Adolescent Psychopharmacology, 2014 May;24(4):190-200.

16. Brenner SL, Burns BJ, Curry JF, Silva SG, Kratochvil CJ, Domino MA, (2014). Mental Health Service Use Among Adolescents Following Participation in a Randomized Clinical Trial for Depression, J of Clinical Child and Adolescent Psychology. 2015;44(4):551-8.

17. Kratochvil CJ. ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk. Am J Psychiatry. 2012 Feb;169(2):112-4.

18. Prakash A, Lobo E, Kratochvil CJ, Tamura RN, Pangallo BA, Bullok KE, Quinlan T, Emslie GJ, March JS. An open-label safety and pharmacokinetics study of duloxetine in


25

pediatric patients with major depression. J Child Adolesc Psychopharmacol. 2012 Feb;22(1):48-55.

19. Vaughan B, Kratochvil CJ (2012). Pharmacotherapy of Pediatric Attention-Deficit/Hyperactivity Disorder. Child Adolesc Psychiatr Clin N Am. 2012 Oct;21(4):941-55.

20. Curry, J., Silva, S., Rohde, P., Ginsburg, G., Kennard, B., Kratochvil, C., Simons, A., Kirchner, J., May, D., Mayes, T., Feeny, N., Albano, A. M., Lavanier, S., Reinecke, M., Jacobs, R., Becker-Weidman, E., Weller, E., Emslie, G., Walkup, J., Kastelic, E., Burns, B., Wells, K., & March, J. (2012). Onset of Alcohol or Substance Use Disorders Following Treatment for Adolescent Depression. Journal of Consulting and Clinical Psychology. 2012 Apr;80(2):299-312.

21. Apostol G, Abi-Saab W, Kratochvil CJ, Adler LA, Robieson WZ, Gault LM, Pritchett YL, Feifel D, Collins MA, Saltarelli MD (2012). Efficacy and safety of the novel α(4)β (2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl). 2012 Feb;219(3):715-25.

22. Curry J, Silva S, Rohde P, Ginsburg G, Kratochvil C, Simons A, Kirchner J, May D, Kennard B, Mayes T, Feeny N, Albano AM, Lavanier S, Reinecke M, Jacobs R, Becker-Weidman E, Weller E, Emslie G, Walkup J, Kastelic E, Burns B, Wells K, March J. Recovery and recurrence following treatment for adolescent major depression. Arch Gen Psychiatry. 2011 Mar;68(3):263-9.

23. Correll CU, Kratochvil CJ, March JS (2011). Developments in Pediatric Psychopharmacology: Focus on Stimulants, Antidepressants, and Antipsychotics. J Clin Psychiatry. 2011 May;72(5):655-70.

24. Kratochvil CJ, Vaughan, B, Stoner J, Daughton, JM, Lubberstedt B, Murray D, Chrisman A, Faircloth J, Itchon-Ramos N, Kollins S, Maayan L, Greenhill L, Kotler L, Fried J March J (2011). A Double-Blind, Placebo-Controlled Study of Atomoxetine in Young Children with ADHD. Pediatrics. 2011 Apr;127(4):e862-8.

25. Vaughan BS, March JS, Kratochvil CJ The Evidence-Based Pharmacological Treatment of Pediatric ADHD. Int J Neuropsychopharmacol. 2012 Feb;15(1):27-39.

26. Wilens TE, Gault LM, Childress A, Kratochvil CJ, Bensman L, Hall CM, Olson E, Roieson WZ, Garimella TS, Abi-Saab WM, Apostol G, Saltarelli MD (2011). Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials. J Am Acad Child Adolesc Psychiatry. 2011 Jan;50(1):73-84.e1.

27. May DE, Kratochvil CJ (2010). Attention-Deficit/Hyperactivity Disorder: Recent Advances in Pediatric Pharmacotherapy. Drugs 2010;70(1):15-40.

28. Yu ZJ, Kratochvil CJ, Weller RA, Mooreville M, Weller EB (2010). From TADS and SOFTADS to TORDIA and Beyond: What’s New in the Treatment of Adolescent Depression. Curr Psychiatry Rep. 2010 Apr;12(2):88-95.

29. Daughton J, Liu H, West M, Swanson D, Kratochvil CJ (2010).Practical Guide to ADHD Pharmacotherapy. Psychiatric Annals 40(4):210-217.

30. Feeney NC, Silva SG, Reinecke MA, McNulty S, Findling RL, Rohde P, Curry JF, Ginsburg GS, Kratochvil CJ, Pathak S, May D, Kennard E, Simons AD, Wells K, Robins M, Rosenberg D, March JS. An Exploratory Analysis of Impact on Family Functioning on Treatment for Depression in Adolescents. J Clin Child Adolesc Psychology. 2009 Nov;38(6):814-25.

31. Kratochvil CJ, May DE, Silva SG, Madaan V, Puumala SE, Curry JF, Walkup J, Kepley H, Vitiello B, March JS (2009). Treatment Response in Depressed Adolescents with and without Co-Morbid Attention-Deficit/Hyperactivity Disorder in the Treatment for Adolescents with Depression Study. J Child Adolesc Psychopharm. 2009 Oct;19(5):519-27.


26

32. Newcorn JH, Sutton VK, Zhang S, Wilens T, Kratochvil C, Emslie GJ, D’Souza DN, Schuh LM, Allen AJ (2009). Characteristics of Placebo Responders in Pediatric Clinical Trials of Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2009 Dec;48(12):1165-72.

33. Treatment for Adolescents With Depression Study (TADS) Team, The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry. 2009 Oct;166(10):1141-9.

34. Daughton JM, Kratochvil CJ (2009). Review of ADHD Pharmacotherapies: Advantages, Disadvantages, and Clinical Pearls. J Am Acad Child Adolesc Psychiatry. 2009 Mar;48(3):240-8.

35. Kratochvil CJ, Vaughan BS, Barker A, Corr L, Wheeler A, Madaan V (2009). Review of Pediatric Attention Deficit/Hyperactivity Disorder for the General Psychiatrist. Psychiatr Clin North Am. 2009 Mar;32(1):39-56.

36. Schonfeld TL, Amoura NJ, Kratochvil CJ (2009). iPLEDGE Allegiance to the Pill: Evaluation of Year 1 of a Birth Defect Prevention and Monitoring System. J Law Med Ethics. 2009 Spring;37(1):104-17.

37. Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, Reinecke MA, March JS. (2009) The Relative Cost-Effectiveness of Treatment for Adolescent Depression: 36-week Results from the TADS Randomized Trial. J Am Acad Child Adolesc Psychiatry. 2009 Jul;48(7):711-20.

38. Vaughan BS, Fegert JM, Kratochvil CJ (2009). Update on Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder. Expert Opin Pharmacother. 2009 Mar;10(4):669-76.

39. Vitiello B, Silva S, Rohde P, Kratochvil C, Kennard B, Reinecke M, Mayes T, Posner K, May DE, March JS (2009). Suicidal Events in the Treatment for Adolescents with Depression Study (TADS). J Clin Psychiatry 2009 Apr 21;70(5):741-7.

40. Kennard BD, Silva SG, Mayes T, Rohde P, Hughes JL, Vitiello B, Kratochvil CJ, Curry JF, Emslie GJ, Reinecke MA, March JS (2009). Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. Am J Psychiatry. 2009 Mar;166(3):337-44.

41. Rogers GM, Park JH, Essex MJ, Klein MH, Silva SG, Hoyle RH, Curry JF, Feeny NC, Kennard B, Kratochvil CJ, Pathak S, Reinecke MA, Rosenberg DR, Weller EB, March JS (2009). The dysfunctional attitudes scale: psychometric properties in depressed adolescents. J Clin Child Adolesc Psychology 2009 Nov;38(6):781-9.

42. Domino ME, Burns BJ, Mario J, Reinecke MA, Vitiello B, Weller EB, Kratochvil CJ, May D, Feeny N, Robins M, Hallin M, Silva SG, March JS. (2009). Service use and costs of care for depressed adolescents: Who uses and who pays? J Clin Child Adolesc Psychology 2009 Nov;38(6):826-36.

43. Jacobs RH, Silva SG, Reinecke MA, Curry JF, Ginsburg GS, Kratochvil CJ, March JS (2009). DAS Perfectionism: A predictor and partial mediator of acute treatment outcome among clinically depressed adolescents. J Clin Child Adolesc Psychology 2009 Nov;38(6):803-13.

44. Kennard BD, Silva SG, Tonev S, Rohde P, Hughes JL, Vitiello B, Kratochvil CJ, Curry JF, Emslie GJ, Reinecke M, March JS (2009). Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): Acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry 2009 Feb;48(2):186-95.

45. Findling RL, Arnold LE, Greenhill LL, Kratochvil CJ, McGough JJ. Diagnosing and managing complicated ADHD. Prim Care Companion J Clin Psychiatry. 2008;10(3):229-36.

46. Faraone SV, Doyle AE, Lasky-Su J, Sklar PB, D'Angelo E, Gonzalez-Heydrich J, Kratochvil C, Mick E, Klein K, Rezac AJ, Biederman J. Linkage analysis of attention


27

deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1387-91.

47. Jacobs R, Klein J, Reinecke M, Silva SG, Tonev S, Breland-Noble A, Martinovich Z, Kratochvil CJ, Rezak AJ, Jones J, March JS (2008). Ethnic differences in attributions and treatment expectancies for adolescent depression. Int J Cog Therapy 2008 Jun;1(2):163-178.

48. Zito J, Derivan A, Kratochvil C, Safer D, Fegert J, Greenhill L (2008). Off-label Psychopharmacologic Prescribing for Children: History Supports Close Clinical Monitoring. Child Adolesc Psychiatry Ment Health, 2008 Sep 15;2(1):24.

49. Kratochvil C, Milton D, Vaughan B, Greenhill L (2008). Acute Atomoxetine Treatment of Younger and Older Children With ADHD: A Meta-Analysis of Tolerability and Efficacy. Child Adolesc Psychiatry Ment Health, 2008 Sep 15;2(1):25.

50. Domino ME, Burns BJ, Silva SG, Kratochvil CJ, Vitiello B, Reinecke MA, Mario J, March J (2008). The Cost-Effectiveness of Treatments for Adolescent Depression: Results from the Treatment for Adolescents with Depression Study (TADS). Am J Psychiatry. 2008 May;165(5):588-96.

51. Rohde P, Silva SG, Tonev ST, Kennard BD, Vitiello B, Kratochvil CJ, Reinecke MA, Curry JF, Simons AD, March JS (2008). Achievement and Maintenance of Sustained Response During the Treatment for Adolescents with Depression Study (TADS) Continuation and Maintenance Therapy. Arch Psychiatry. 2008 Apr;65(4):447-55.

52. Vaughan BS, Wetzel MW, Kratochvil CJ (2008). Beyond the ‘Typical’ Patient: Treating Attention-Deficit/Hyperactivity Disorder in Preschoolers and Adults. Int Rev Psychiatry. 2008 Apr;20(2):143-9.

53. Greenhill LL, Posner K, Vaughan BS, Kratochvil CJ (2008). Attention deficit hyperactivity disorder in preschool children. Child Adolesc Psychiatric Clin N Am. 2008 Apr;17(2):347-66, ix.

54. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D, Atomoxetine/Methylphenidate Comparative Study Group (2008). Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response. Am J Psychiatry. 2008 Jun;165(6):721-30.

55. Dell ML, Vaughan BS, Kratochvil CJ (2008). Ethics and the Prescription Pad. Child Adolesc Psychiatric Clin N Am, 2008 Jan;17(1):93-111, ix. Review.

56. Bhatia SK, Rezac AJ, Vitiello B, Sitorius MA, Buehler BA, Kratochvil CJ (2008). Antidepressant Prescribing Practices for the Treatment of Children and Adolescents. J Child Adolesc Psychopharmacology. 2008 Feb;18(1):70-80.

57. Perwien AR, Kratochvil CJ, Faries D, Vaughan B, Busner J, Saylor KE, Buermeyer CM, Kaplan S, Swindle R (2008). Emotional Expression in Children Treated with ADHD Medication: Development of a New Measure. J of Attention Disorders 2008 Mar;11(5):568-79.

58. Madaan V, Daughton J, Lubberstedt B, Mattai A, Vaughan BS, Kratochvil CJ (2008) Assessing the Efficacy of Treatments for ADHD: Overview of Methodological Issues. CNS Drugs, 2008;22(4):275-90.

59. Findling RL, Arnold LE, Greenhill LL, Kratochvil CJ, McGough JJ. Diagnosing and managing complicated ADHD. J Clin Psychiatry. 2007 Dec;68(12):1963-70.

60. Compton SN, Kratochvil CJ, March JS (2007). Pharmacotherapy for Anxiety Disorders in Children and Adolescents: An Evidence-Based Medicine Review. Psychiatric Annals, 2007 Sep;36(9):586-90, 592, 594-8.

61. Vitiello B, Kratochvil CJ, Silva S, Curry J, Reinecke M, Pathak S, Waslic B, Hughes C, Prentice ED, May DE, March JS (2007). Research Knowledge Among the Participants in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2007 Dec;46(12):1642-50.


28

62. DelBello MP, Correll CU, Carlson GA, Carlson HE, Kratochvil CJ (2007). Pharmacological Management of Bipolar Disorder in a Youth with Diabetes J Am Acad Child Adolesc Psychiatry, 2007 Oct;46(10):1375-9.

63. Emslie GJ, Waslick B, Weller EB, Kloos A, Weller RA, Kratochvil CJ (2007). Antidepressant Management in the Context of Suicidal Ideation. J Am Acad Child Adolesc Psychiatry, 2007 Sep;46(9):1222-5.

64. Spencer TJ, Kratochvil CJ, Sangal RB, Saylor KE, Bailey CE, Dunn DW, Casat CD, Lipetz RS, Jain R, Newcorn JH, Ruff DD, Feldman PD, Furr AJ, Allen AJ (2007). Effects of Atomoxetine on Growth in Children with ADHD Following up to Five Years of Treatment. J Child Adolesc Psychopharmacology, 2007 Oct;17(5):689-700.

65. Kratochvil CJ, Michelson D, Newcorn JH, Weiss MD, Busner J, Moore RJ, Ruff DD, Ramsey J, Dickson R, Turgay A, Saylor KE, Luber S, Vaughan B, Allen AJ, and the Atomoxetine High-dose Study Group (2007). High-dose Atomoxetine Treatment of ADHD in Youths with Limited Response to Standard Doses. J Am Acad Child Adolesc Psychiatry, 2007 Sep;46(9):1128-37.

66. May DM, Hallin MJ, Kratochvil CJ, Puumala SE, Reinecke MA, Silva SG, Weller EB, Vitiello B, Breland-Nobel A, March JS (2007). Factors Associated with Recruitment and Screening in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2007 Jul;46(7):801-10.

67. Kratochvil CJ, Vaughan BS, Mayfield-Jorgensen ML, March JS, Kollins SH, Murray DW, Ravi H, Greenhill LL, Kotler LA, Paykina N, Biggins P, Stoner J. (2007). A Pilot Study of Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol 2007 Apr;17(2):175-85.

68. March JS, Szatmari P, Bukstein O, Chrisman A, Kondo D, Hamilton J, Kremer CME, Kratochvil CJ (2007). AACAP 2005 Research Forum: speeding the Adoption of Evidence-Based Practice in Pediatric Psychiatry. J Am Acad Child Adolesc Psychiatry, 2007 Sep;46(9):1098-110.

69. Findling RL, Newcorn JH, Malone RP, Waheed A, Prince JB, Kratochvil CJ (2007). Pharmacotherapy of Aggression in a 9-year-old with ADHD. J Am Acad Child Adolesc Psychiatry 2007 May;46(5):653-8.

70. March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007 Oct;64(10):1132-43. Erratum in: Arch Gen Psychiatry. 2008 Jan;65(1):101.

71. May DE, Kratochvil CJ, Puumala SE, Silva SG, Rezac AJ, Hallin MJ, Reinecke MA, Vitiello B, Pathak S, Simons AD, Weller EB, March JS (2007). A Manual-Based Intervention to Address Clinical Crises and Retain Patients in the Treatment of Depression for Adolescents Study (TADS) J Am Acad Child Adolesc Psychiatry 2007 May;46(5):573-81.

72. Kratochvil CJ, Faries D, Vaughan B, Perwien A, Busner J, Saylor K, Kaplan S, Buermeyer C, Swindle R (2007). Emotional Expression During Attention-Deficit/Hyperactivity Disorders Treatment: Initial Assessment of Treatment Effects. J Child Adolesc Psychopharmacol 2007 Feb;17(1):51-62.

73. Findling RL, Frazier JA, Gerbino-Rosen G, Kranzler HN, Kumra S, Kratochvil CJ (2007). Is there a role for clozapine in the treatment of children and adolescents? J Am Acad Child Adolesc Psychiatry 2007 Mar;46(3):423-8.

74. Vitiello B, Rohde P, Silva S, Wells K, Casat C, Waslick B, Simons A, Reinecke M, Weller E, Kratochvil C, Walkup J, Pathak S, Robins M, March J; TADS Team. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1419-26.

75. Gonzalez-Heydrich J, Weiss M, Connolly M, Wambera K, Jan JE, Plioplys S, Dunn DW, Kratochvil CJ (2006). Pharmacological Management of a Youth with ADHD and a Seizure


29

Disorder. J Am Acad Child Adolesc Psychiatry 2006 Dec;45(12):1527-32. 76. Vaughan B, Kratochvil CJ (2006). Pharmacotherapy of ADHD in Young Children.

Psychiatry (Edgmont). 2006 Aug;3(8):36-45. 77. Madaan V, Kinnan S, Daughton J, Kratochvil CJ (2006). Innovations and Recent Trends in

the Treatment of ADHD: A Review. Expert Review of Neurotherapeutics 2006 Sep;6(9):1375-85. Review.

78. Kratochvil CJ, Emslie GJ, Silva SG, McNulty S, Walkup J, Curry J, Reinecke MA, Vitiello B, Rohde P, Feeney NC, Casat C, Pathak S, Weller E, May D, Mayes TL, Robins M, March JS and the TADS Team (2006). Acute Time to Response in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006 Dec;45(12):1412-8.

79. Newcorn JH, Michelson D, Kratochvil CJ, Allen AJ, Ruff DD, Moore RJ and the Atomoxetine Study Group (2006). Low-dose Atomoxetine for Maintenance Treatment of ADHD. Pediatrics. 2006 Dec;118(6):e1701-6.

80. Deupree JD, Smith SD, Kratochvil CJ, Bohac D, Ellis CR, Polaha J and Bylund DB (2006) Possible Involvement of Alpha-2A Adrenergic Receptors in Attention Deficit Hyperactivity Disorder: Radioligand Binding and Polymorphism Studies. Am J Med Genetics Part B (Neuropsychiatric Genetics). 2006 Dec 5;141B(8):877-84.

81. Sankaranarayanan JM.Pharm, Puumala SE, Kratochvil, CJ (2006). Diagnosis and Treatment of Adult Attention-Deficit/Hyperactivity Disorder in US Ambulatory Care from 1996 to 2003. Current Medical Research and Opinion. 2006 Aug;22(8):1475-91.

82. Kratochvil CJ, Wilens TE, Upadhyaya H (2006). Pharmacological Management of a Youth with ADHD, Marijuana Use, and Mood Symptoms. J Am Acad Child Adolesc Psychiatry 2006 Sep;45(9):1138-41.

83. Emslie GJ, Kratochvil CJ, Vitiello B, Silva SG, Mayes TL, McNulty S, Weller E, Waslick B, Casat C, Walkup J, Pathak S, Rohde P, Posner K, March J, Columbia Suicidality Classification Group and the TADS Team (2006). Treatment for Adolescents with Depression Study (TADS): Safety Results. J Am Acad Child Adolesc Psychiatry 2006 Dec;45(12):1440-55.

84. Kennard BD, Silva SG, Vitiello B, Curry J, Kratochvil CJ, Simons A, Hughes JL, Feeny N, Weller EB, Sweeney M, Reinecke M, Pathak S, Ginsburg GS, Emslie GJ, March J, and the TADS Team (2006). Remission and Residual Symptoms after Acute Treatment of Adolescents with Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 2006 Dec;45(12):1404-11.

85. March JS, Silva SG, Vitiello B, and the TADS Team (2006). The Treatment for Adolescents with Depression Study (TADS): Methods and Message at Twelve Weeks. J Am Acad Child Adolesc Psychiatry 2006 Dec;45(12):1393-403.

86. Vitiello B, Rohde P, Silva SG, Wells KC, Casat C, Waslick B, Simons A, Reinecke MA, Weller E, Kratochvil CJ, Walkup J, Pathak S, Robins M, March J, and the TADS Team (2006). Effects of Treatment on Level of Functioning, Global Health, and Qualify of Life in Depressed Adolescents. J Am Acad Child Adolesc Psychiatry 45(12):1419-1426.

87. Curry JF, Rohde P, Simons A, Silva SG, Vitiello B, Kratochvil CJ, Reinecke MA, Feeny N, Wells KC, Pathak S, Weller E, Rosenberg D, Kennard BD, Robins M, Ginsburg GS, March JS, and the TADS Team (2006). Predictors and Moderators of Acute Outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006 Dec;45(12):1427-39.

88. Kratochvil CJ, Kazura A, Deas D, Martin CA, Dosh T, Wilens TE (2006). Pharmacological Management of a Teen with Significant Alcohol Use and Depression. J Am Acad Child Adolesc Psychiatry. 2006 Aug;45(8):1011-5.

89. Perwien AR, Kratochvil CJ, Faries DE, Vaughan BV, Spencer T, Brown RT (2006). Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: What are the long-term health-related quality of life outcomes? J Child Adolesc Psychopharm. 2006 Dec;16(6):713-24.


30

90. Wilens T, Newcorn J, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, Feldman P, Levine L (2006). Long-term Atomoxetine Treatment in Adolescents with Attention-Deficit/Hyperactivity Disorder. J Pediatrics. 2006 Jul;149(1):112-9.

91. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, Gelowitz DL (2006). Effects of Long-term Atomoxetine Treatment for Young Children with Attention-Deficity/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2006 Aug;45(8):919-27.

92. Brown RT, Perwien A, Faries DE, Kratochvil CJ, Vaughan BS (2006). Atomoxetine in the Management of Children with ADHD: Effects on Quality of Life and School Functioning. Clin Pediatr. 2006 Nov;45(9):819-27.

93. Kratochvil CJ, Varley C, Cummins TK, Martin A (2006). Less is More: Inpatient Management of a Child with Complex Pharmacotherapy. J Am Acad Child Adolesc Psychiatry 2006 May;45(5):621-4.

94. Wilens TE, Kratochvil CJ, Newcorn J, Thomason C, Gao H (2006). Do Children and Adolescents with ADHD Respond Differently to Atomoxetine? J Am Acad Child Adolesc Psychiatry. 2006 Feb;45(2):149-57.

95. Kratochvil CJ, Vitiello B, Walkup J, Emslie G, Waslick BD, Weller EB, Burke WJ, March JS (2006). SSRIs in Pediatric Depression: Is the Balance Between Benefits and Risks Favorable? J Child Adolesc Psychopharm. 2006 Feb-Apr;16(1-2):11-24.

96. Kratochvil CJ, Vitiello B, Brent D, Bostic JQ, Naylor MW (2006). Selecting an Antidepressant for the Treatment of Pediatric Depression. J Am Acad Child Adolesc Psychiatry, 2006 Mar;45(3):371-3.

97. Kratochvil CJ, March J, Prentice E (2006). Guidance for IRB’s on Placebo and Alternatives to Placebo in Randomized Controlled Trials. The Bureau of National Affairs, 5(6):220-224.

98. Wilens T, McBurnett K, Buckstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper K, Lynch JM (2006). A Multisite, Controlled Trial of OROS® Methylphenidate (CONCERTA®) in the Treatment of Adolescents with Attention-Deficit/Hyperactivity Disorder. Arch Ped Adolesc Med, 2006

Jan;160(1):82-90. 99. Kratochvil CJ, Egger H, Greenhill LL, McGough (2006). Pharmacological Management

of Preschool ADHD. J Am Acad Child Adolesc Psychiatry, 2006 Jan;45(1):115-8. 100. Pathak S, Kratochvil CJ, Rogers GM, Silva S, Vitiello B, Weller EB, March JS

(2005). Comparative Efficacy of Cognitive Behavioral Therapy, Fluoxetine, and Their Combination in Depressed Adolescents: Initial Lessons from the Treatment for Adolescents with Depression Study. Curr Psychiatry Rep, 2005 Dec;7(6):429-34.

101. Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill LL (2005). Efficacy and Safety of Modafinil Film-Coated Tablets in Children and Adolescents with Attention-Deficity/Hyperactivity Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study. Pediatrics, 2005 Dec;116(6):e777-84.

102. Kratochvil CJ, DelBello M, Upadhyaya H, Wozniak J (2005). Pharmacological Management of New-Onset Bipolar Disorder. J Am Acad Child Adolesc Psychiatry, 2005 Nov;44(11):1198-200.

103. Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J (2005). Atomoxetine alone or combined with fluoxetine for treating ADHD and comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry, 2005 Sep;44(9):915-24.

104. Kratochvil CJ, Findling RL, McDougle CJ, Scahill L, Hamarman S (2005). Pharmacological management of agitation and aggression in an adolescent with autism. J Am Acad Child Adolesc Psychiatry, 2005 Aug;44(8):829-32.


31

105. Kratochvil CJ, Simons A, Vitiello B, Walkup J, Emslie G, Rosenberg D, March JS (2005). A multi-site psychotherapy and medication trial for depressed adolescents: Background and benefits. Cognitive and Behavioral Practice. 12:159-165.

106. Ginsburg GS, Albana AM, Findling RL, Walkup J, Kratochvil C (2005). Integrating cognitive behavioral therapy and pharmacotherapy in the treatment of adolescent depression. Cognitive and Behavioral Practice. 12:252-262

107. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ (2005). A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005 Jul;44(7):647-55.

108. Kratochvil CJ, Lake M, Pliszka SR, Walkup JT (2005). Psychopharmacology perspectives: Pharmacological management of treatment-induced insomnia in ADHD. J Am Acad Child Adolesc Psychiatry, 2005 May;44(5):499-501.

109. Spencer T, Newcorn J, Kratochvil C, Ruff D, Michelson D, Biederman J (2005). Effects of atomoxetine on growth after 2-year treatment in pediatric patients with ADHD. Pediatrics 2005 Jul;116(1):e74-80.

110. Polaha J, Cooper S, Meadows T, Kratochvil C (2005). The assessment of attention-deficit/hyperactivity disorder in rural primary care: The portability of the American Academy of Pediatrics guidelines to the ‘real world.’ Pediatrics 2005 Feb;115(2):e120-6.

111. Kratochvil CJ, Dineen Wagner K, Emslie G, March J (2005). Pharmacological management of treatment-resistant pediatric depression. J Am Acad Child Adolesc Psychiatry, 2005 Feb;44(2):198-200.

112. Treatment for Adolescents with Depression Study (TADS) Team (2005). The treatment for adolescents with depression study (TADS): Demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry, 44(1):28-40.

113. Kratochvil CJ, Greenhill LL, March JS, Burke WJ, Vaughan BS (2004). The role of stimulants in the treatment of preschool children with attention-deficit hyperactivity disorder. CNS Drugs, 2004:18(14):957-66.

114. Treatment for Adolescents with Depression Study (TADS) Team (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for adolescents with depression study (TADS) randomized controlled trial. Journal of the American Medical Association, 292:807-820.

115. Kratochvil CJ, Vaughan BS, Daughton JM, Mayfield-Jorgensen ML, Burke WJ (2004). Atomoxetine in the treatment of attention deficit hyperactivity disorder. Expert Rev Neurotherapeutics, 2004 Jul;4(4):601-11.

116. March J, Kratochvil C, Clarke G, Beardslee W, Derivan A, Emslie G, Green EP, Heiligenstein J, Hinshaw S, Hoagwood K, Jensen P, Lavori P, Leonard H, McNulty J, Michaels A, Mossholder A, Osher T, Petti T, Prentice E, Vitiello B, Wells K (2004). AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric pharmacology. Journal of the American Academy of Child & Adolescent Psychiatry, 2004 Aug;43(8):1046-56.

117. Hinshaw SP, Hoagwood K, Jensen PS, Kratochvil C, Bickman L, Clarke G, Abikoff HB, Atkins M, Vitiello B (2004). AACAP 2001 research forum: challenges and recommendations regarding recruitment and retention of participants in research investigations. Journal of the American Academy of Child & Adolescent Psychiatry, 2004 Aug;43(8):1037-45.

118. Matza LS, Rentz AM, Swensen AR, Secnik K, Revicki DA, Michelson D, Spencer T, Newcorn J, Kratochvil CJ (2004). The link between health-related quality of life and clinical symptoms in children with ADHD. Journal of Developmental and Behavioral Disorders, 2004 Jun;25(3):166-74.

119. Perwien AR, Faries DE, Kratochvil CJ, Sumner CR, Kelsey DK, Allen AJ (2004). Improvement in health-related quality of life in children with ADHD: an analysis of placebo-


32

controlled studies of atomoxetine. Journal of Developmental and Behavioral Pediatrics, 2004 Aug;25(4):264-71.

120. Lowe N, Kirley A, Hawi Z, Sham P, Wickham H, Kratochvil CJ, Smith SD, Lee SY, Levy F, Kent L, Middle F, Rohde LA, Roman T, Tahir E, Yazgan Y, Asherson P, Mill J, Thapar A, Payton A, Todd RD, Stephens T, Ebstein RP, Manor I, Barr CL, Wigg KG, Sinke RJ, Buitelaar JK, Smalley SL, Nelson SF, Biederman J, Faraone SV, Gill M (2004). Joint analysis of DRD5 marker concludes association with ADHD confined to the predominantly inattentive and combined subtypes. American Journal of Human Genetics, 2004 Feb;74(2):348-56.

121. Kratochvil CJ, Vaughan BS, Harrington MJ, & Burke WJ (2003). Atomoxetine: a selective norepinephrine reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opinion on Pharmacology, 2003 Jul;4(7):1165-74.

122. Kratochvil CJ, Harrington MJ, Burke WJ, & Vaughan BS (2003). Atomoxetine: treatment of attention-deficit/hyperactivity disorder through selective norepinephrine reuptake inhibition. Today’s Therapeutic Trends, 21:239-250.

123. Biederman J, Kratochvil CJ, Spencer TJ, & Wozniak J (2003). Determining and achieving therapeutic targets in attention-deficit/hyperactivity disorder. Academic Highlights section of Journal of Clinical Psychiatry, 64:265-276.

124. The Treatment of Adolescent Depression Study (TADS) Team (2003). Treatment for adolescents with depression study (TADS): rationale, design and methods. Journal of the American Academy of Child & Adolescent Psychiatry, 42:531-542.

125. Greenhill LL, Jensen PS, Abikoff H, Blumer JL, DeVeaugh-Geiss J, Fisher C, Hoagwood K, Kratochvil CJ, Lahey BB, Laughren T, Leckman J, Petti TA, Pope K, Shaffer D, Vitiello B, & Zeanah C (2003). Developing strategies for psychopharmacological studies in preschool children. Journal of the American Academy of Child & Adolescent Psychiatry, 2003 Apr;42(4):406-14.

126. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002 Nov;159(11):1896-901.

127. Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776-84.

128. Biederman J, Heiligenstein J, Faries D, Galil N, Dittman R, Emslie GJ, Kratochvil C, Laws H, Schuh KJ, & the Atomoxetine Study Group (2002). Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics, 2002 Dec;110(6):e75.

129. Spencer JT, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, & Potter WZ (2002). Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 2002 Dec;63(12):1140-7.

130. Wernicke JF & Kratochvil, CJ (2002). Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. Journal of Clinical Psychiatry, 2002;63 Suppl 12:50-5. Review.

131. Kratochvil CJ, Harrington MJ, Burke WJ, March JS (2002). Pharmacotherapy of childhood anxiety disorders. Current Psychiatric Reports, 2002 Aug;4(4):264-9.

132. Michelson D, Allen AJ, Kelsey D, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West D, Wernicke J, Raute N, & Harder D (2002). Safety and efficacy of once-daily atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder. American Journal of Psychiatry, 159:1896-1901.


33

133. Burke WJ, Kratochvil CJ (2002). Stereoisomers in psychiatry. The case of escitalopram. Primary Care Companion to the Journal of Clinical Psychiatry. 2002 Feb;4(1):20-24.

134. Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776-84.

135. Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, Jacobson JG, and the Fluoxetine Pediatric OCD Study Team (2001). Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. Journal of the American Academy of Child & Adolescent Psychiatry, 40(7):773-779.

136. Kratochvil CJ, Bohac D, Harrington M, Baker N, May D, & Burke WJ (2001). An open-label trial of atomoxetine in pediatric ADHD. Journal of Child and Adolescent Psychopharmacology. 11 (2):167-170.

137. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, & the Atomoxetine Study Group (2000). Atomoxetine in the treatment of children with ADHD: a randomized, placebo-controlled dose response study. Pediatrics. 108 (5) e83.

Book Edited

1. Nebraska Isolation & Quarantine Manaul, Cieslak TJ, Kortepeter MG, Kratochvil CJ, Lawler JV Editors, 2019.

2. Pediatric Psychopharmacology: Principles and Practice, 2nd Edition, Martin A, Scahill L, Kratochvil CJ Editors, Oxford Press, 2011.

Book Chapters

1. Vaughan BS, Daughton JD, Kratochvil CJ. Preschool ADHD Treatment. In Attention-Deficit Hyperactivity Disorder in Adults and Children. Edited by Adler, Spencer and Wilens; Cambridge University Press, 2015.

2. Daughton J, Kratochvil CJ. Stimulants. In Pediatric Psychopharmacology: Principles and Practice, 2nd Edition. Edited by Martin, Scahill and Kratochvil; Oxford Press, 2011.

3. Carandang CG, Kratochvil CJ, Scahill L, Martin A. Running a Pediatric Psychopharmacology Clinic: Practical Aspects. In Pediatric Psychopharmacology: Principles and Practice, 2nd Edition. Edited by Martin, Scahill and Kratochvil; Oxford Press, 2011.

4. Kratochvil CJ, Wells K, March JS. Combining Pharmacotherapy and Psychotherapy: An Evidence-based Approach. In Pediatric Psychopharmacology: Principles and Practice, 2nd Edition. Edited by Martin, Scahill and Kratochvil; Oxford Press, 2011.

5. Dell ML, Vaughan BS, Kratochvil CJ. Ethical Issues in Pediatric Psychopharmacology Research. In Pediatric Psychopharmacology: Principles and Practice, 2nd Edition. Edited by Martin, Scahill and Kratochvil; Oxford Press, 2011.

6. Brent DA, Stark KD, Kratochvil CJ. I Just Want to Die: Double Depression. In DSM-IV-TR Casebook and Treatment Guide for Child Mental Health. Edited by Galanter CA & Jensen PS; American Psychiatric Publishing, 2009; pp. 403-418.

7. Kratochvil CJ and Wetzel M. Attention-Deficit/Hyperactivity Disorder. In Conn’s Current Therapy 2009. Edited by Rakel RE & Bope E; Saunders, Elsevier, 2009; pp. 916-918.

8. Kratochvil CJ, Prentice ED, Gordon BG, & Kotulak GD. Regulatory Issues of Research Involving Prisoners. In Institutional Review Board: Member Handbook, Second Edition. Edited by Andur RJ & Bankert EA; Jones & Bartlett Publishers, 2007; pp. 181-185.


34

9. Gordon BG, Brown J, Kratochvil C, Prentice ED & Amdur RJ. Paying Research Subjects. In Institutional Review Board: Member Handbook, Second Edition. Edited by Andur RJ & Bankert EA; Jones & Bartlett Publishers, 2007; pp.107-113.

10. Kratochvil CJ, Prentice ED, Epperson KJ, Gordon BG. Institutional Review Board Review of Adverse Events. In Institutional Review Board: Management and Function, Second Edition. Edited by Bankert EA and Amdur RJ; Jones & Bartlett Publishers, 2007; 257-261.

11. Kratochvil C. Contributing author (questions and text). Study Guide for Institutional Review Board Management and Function. Edited by Davis AL, Bankert EA, Hansen K, Kornetsky S, McGough H; Jones & Bartlett Publishers, 2006.

12. Kratochvil, C., Harrington, M. Adolescent Interpersonal Relationships. In Textbook of Adolescent Psychiatry. Edited by Richard Rosen: Arnold, London, 2003; pp. 193-198.

13. Kratochvil, C. Contributing author (questions and text). Study Guide for Institutional Review Board: Management and Function. Edited by Kornetsky S, Davis A, & Amdur RJ; Jones & Bartlett Publishers, 2002.

14. Gordon B, Brown J, Kratochvil CJ, & Prentice E: Paying research subjects. In Institutional Review Board: Member Handbook. Edited by Andur R; Jones & Bartlett Publishers, 2002; pp.105-112.

15. Prentice ED, Gordon BG, Kratochvil CJ, & Kotulak GD: Research involving prisoners. In Institutional Review Board: Member Handbook. Edited by Andur R; Jones & Bartlett Publishers, 2002; pp. 171-174.

16. Prentice ED, Epperson KJ, Kratochvil CJ, & Gordon B: IRB review of adverse events. In Institutional Review Board: Management and Function. Edited by Andur R and Banker E; Jones & Bartlett Publishers, 2002; pp.297-302.

17. Gordon B, Brown J, Kratochvil CJ, & Prentice E: Paying research subjects. In Institutional Review Board: Management and Function. Edited by Andur R and Banker E; Jones & Bartlett Publishers, 2002; pp.185-190.

18. Prentice ED, Gordon BG, Kratochvil CJ, & Kotulak GD: Research involving prisoners. In Institutional Review Board: Management and Function. Edited by Andur R and Banker E,;Jones & Bartlett Publishers, 2002; pp. 394-398.

19. Kratochvil C, Kutcher S, Reiter S & March JS: Psychopharmacology of pediatric anxiety disorders. In Handbook of Psychotherapies with Children and Families. Edited by Ollendick TH and Russ SW; NY, NY, Kluwer Academic/Plenum Publishers, 1999.

Abstracts and Preliminary Communications

1. Kortepeter MG, Bhadelia N, Cieslak TJ, Dierberg K, Evans JD, Frank MG, Grein J, Kraft CS, Kratochvil CJ, McLellan S, Mehta AK, Sauer L, Davey RT Jr, Shenoy ES. Considering the Medical Countermeasure Options for an Emerging Infectious Disease Before the Patient Arrives – the Special Pathogen Research Network Initiative. Abstract #19-02136 Podium Presentation, Military Health System Research Symposium, Kissimmee, FL, August 19, 2019.

2. Kratochvil, CJ, The Global Center for Health Security: A Model of Global Preparedness for Emerging Infectious Diseases, Abstract no 211, Oral presentation, XV Congress of the Spanish Society of Virology/11th International Meeting GVN, Barcelona, Spain, 9-12, June 2019.

3. Hindt F, Madhavan D, Burbach S, Wichman C, Larson L, Kratochvil C. Open-label Epidiolex Study for Drug-Resistant Seizure Disorder. Nebraska Academy of Family Physicians, 71st Annual Meeting & Scientific Assembly. March 29, 2019

4. Kortepeter MG, Cieslak TJ, Kwon EH, Hewlett AL, Martins KM, Cardile AP, Kratochvil CJ, Kraft CS. The National Ebola Training and Education Center Special Pathogen Research Network (NETEC-SPRN) – An Emerging Infectious Disease Research


35

Opportunity for the DoD. Abstract MHSRS-17-1106. Podium presentation, Military Health Research Symposium (MHSRS), Kissimmee, FL, Aug 27, 2017.

5. Kortepeter MG, Cieslak TJ, Kwon EH, Hewlett AL, Martins KM, Cardile AP, Kratochvil CJ, Kraft CS. The Special Pathogens Research Network. Presented at the 40th BioMedical Advisory Panel (BioMed-P), Kansas City, MO, Oct 2, 2017.

6. Kortepeter MG, Cieslak TJ, Kwon EH, Hewlett AL, Martins KM, Cardile AP, Kratochvil CJ, Kraft CS. The National Ebola Training and Education Center-Special Pathogen Research Network (NETEC-SPRN) – An Emerging Infectious Disease Research Consortium to Improve Pandemic Preparedness. Abstract #LB-5087. Poster Presentation, American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting, Baltimore, MD, Nov 6, 2017.

7. Daniel Parecki, Robert Schwab, MD, Kendra Schmid, PhD, Deborah Meyer, Lani Zimmerman, PhD, RN, Christopher J. Kratochvil, M.D. and Jennifer L Larsen, MD, University of Nebraska Medical Center, Omaha, Nebraska. Poster presentation at the ENDO 2016, Obesity and Patient Activation in Rural and Metropolitan Primary Care Clinics, April 1, 2016

8. Jelden, K.C., Gibbs, S.G., Smith, P.W., Schwedhelm, M.M., Iwen, P.C., Beam, E.L., Kratochvil, C.J., Boulter, K.C., Hewlett, A.L., Lowe, J.J. Caring for patients with Ebola virus: Nebraska Biocontainment Unit student perspective. Poster presentation at the University of Nebraska Medical Center, College of Public Health Student Research Conference, Omaha, Nebraska. April 10, 2015.

9. Jelden, K.C., Gibbs, S.G., Smith, P.W., Schwedhelm, M.M., Iwen, P.C., Beam, E.L., Kratochvil, C.J., Boulter, K.C., Hewlett, A.L., Lowe, J.J. Ebola patient transport and discharge: Nebraska Biocontainment Unit considerations in environmental infection control. Poster presentation at the University of Nebraska Medical Center, College of Public Health Student Research Conference, Omaha, Nebraska. April 10, 2015.

10. Kobac K, Kratochvil C, Stanger C, Kaufman J. Computerized Screening of Comorbidity in Adolescents with Substance or Psychiatric Disorders 33rd annual Anxiety Disorders and Depression Conference; La Jolla, CA, April 6, 2013

11. Humble C, Domino M, Jensen PS, Kratochvil C, Stiles A, Newton T, Wegner L, Wegner S: Changes in Perceptions of Guideline-level Care for ADHD in North Carolina. Annual Meeting of the American Public Health Association, San Francisco, October, 2012

12. Domino M, Humble C, Wegner L, Wegner S, Kratochvil C, Newton T, Stiles A, Jensen P: Changes in ADHD prescribing after psychotropic medication training. Annual Meeting of the American Public Health Association, San Francisco, San Francisco, October, 2012 Humble C, Newton T, Domino M, Jensen P, Wegner L, Kratochvil C, Wegner S, Stiles A. Training providers to increase guideline-level care for ADHD in North Carolina. Presented at the 139th Annual American Public Health Association Meeting and Exposition, Washington, DC, Oct 31, 2011.

13. Wilson, T.W., Wetzel, M.W., White, M.L., May, D.E., Franzen, J., Knott, N.L., Kratochvil, C.J. Abnormal gamma-frequency neuronal responses in ADHD: Evidence from MEG imaging. Presented at the 66th Annual Meeting of the Society of Biological Psychiatry (SoBP), San Francisco, CA, May, 2011. Biological Psychiatry (Suppl.), 69:45S-46S.

14. Franzen, J., May, D.E., Knott, N.L., Kratochvil, C.J., & Wilson, T.W. Increased resting-state gamma-frequency activity in the anterior cingulate and frontal regions in adolescents with attention-deficit/hyperactivity disorder. Presented at the 66th Annual Meeting of the Society of Biological Psychiatry (SoBP), San Francisco, CA, USA, May, 2011. Biological Psychiatry (Suppl.), 69:44S.

15. Wilson, T.W., May, D.E., Knott, N.L., & Kratochvil, C.J. Children with ADHD exhibit reduced attention-based modulation of auditory cortical responses. Presented at the 17th International Conference on Biomagnetism, Dubrovnik, Croatia, 2010. Frontiers in Neuroscience (abstract): Biomag 2010. doi:10.3389/conf.fnins.2010.06.00298


36

16. Humble C, Jensen P, Wegner L, Wegner S, Kratochvil C, Stiles A. Enhancing pediatric psychopharmacology for ADHD in North Carolina’s Medicaid program. Annual Research Meeting of Academy Health, Boston, MA, June 2010.

17. Humble C, Newton T, Domino M, Jensen P, Wegner L, Stiles A, Kratochvil C, Wegner S. Optimizing pediatric psychopharmacology for ADHD in North Carolina. Annual Research Meeting of American Public Health Association, Denver, CO, November 2010.

18. Wegner L, Jensen P, Kratochvil C, Humble C, Wegner S, , Stiles A. Enhancing resident physician training in pediatric psychopharmacology for ADHD. Annual Research Meeting of Academy Health, Seattle, WA, June 2011.

19. Gault LM, Apostol G, Wilens TE, Kratochvil CJ, Robieson WZ, Hall CM, Abi-Saab WM, Saltarelli MD. Safety and Efficacy of ABT-089, a Novel Neuronal Nicotinic Receptor Partial Agonist, in the Treatment of Children with ADHD. March JS, Emslie GJ, Kratochvil CJ, Pangallo BA, Lobo E, Tamura RN, Kogut S, Quinlan T, Prakash A. Annual Meeting of the AACAP, Honolulu, Hawaii, October 26-November 1, 2009

20. Daughton JM, Vaughan B, Barker A, Kratochvil CJ. Long-Acting Stimulant Treatment of ADHD in Young Children. Annual Meeting of the AACAP, Honolulu, Hawaii, October 26-November 1, 2009

21. An Open-label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in Children (7-11 years) and Adolescents (12-17 years) with Major Depressive Disorder. 49th Annual NCDEU Meeting, Hollywood, FL, June 29-July 2, 2009.

22. Connor DF, Spencer T, Kratochvil C, Lopez FA, Lyne A, Tremblay G. Effects of Guanfacine Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms. Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 16-21, 2009.

23. Kratochvil CJ, Vaughan B, Daughton J, Lubberstedt B, Murray D, Chrisman A, Faircloth M, Itchon-Ramos N, March JS, Maayan LA, Greenhill LL, Kotler LA, Fried JE, Stoner J. Atomoxetine vs. Placebo for the Treatment of ADHD in 5- and 6-Year-Old Children. Annual Meeting of the AACAP, Chicago, IL, October 28-Nov 2, 2008

24. Farmer JB, Murray D, Ravi H, Fairclosth M, Kratochvil CJ, Vaughan B, Daughton J, Maayan JL, Kotler JA, Jorgensen M, Strauss T. The Clinical Implications of an Innovative Service Delivery Model for ADHD: Combining Parent Education with Medication Management. Annual Meeting of the AACAP, Chicago, IL, October 28-Nov 2, 2008

25. Apostol G, Adler LA, Abi-Saab W, Wilens TE, Kratochvil CJ, Robieson WZ, Wozniak PJ, Saltarelli M. Patient-Reported and Overall Clinical Improvement Associated with ABT-089 in Adult ADHD. Annual Meeting of the American Psychiatric Association, Washington D.C., May 308, 2008

26. Abi-Saab W, Wilens TE, Apostol G, Kratochvil CJ, Robieson WZ, Pritchett YL, Collins MA, Saltarelli M. Efficacy and Safety of ABT-089 in Adults with Attention-Deficit/Hyperactivity Disorder. Annual Meeting of the American Psychiatric Association, Washington D.C., May 308, 2008

27. Moore CK, Moore RJ, Zdon G, Sutton VK, Kratochvil CJ, Schaeffer J, Riordan HJ. 6-Year Prescribing Trends for Antidepressants in the Pediatric Population. 4th Annual Meeting of the International Society for CNS Clinical Trials and Methodology (ISCTM); Washington, DC; February 25-27, 2008

28. Spencer TJ, Kratochvil CJ, Sangal R, Saylor K, Bailey C, Dunn D, Casat C, Lipetz R, Jain R, Newcorn J, Ruff D, Feldman P, Allen A. Five-Year Effects of Atomoxetine on Growth in Children with ADHD. 13th International Congress of the European Society for Child & Adolescent Psychiatry (ESCAP); Florence, Italy; August 25-29, 2007

29. Kratochvil CJ, Vaughan BS, Mayfield-Jorgensen ML, March JS, Kollins SH, Ravi H, Greenhill LL, Kotler LA, Paykina N, Biggins P, Stoner J. A Pilot Study of Atomoxetine


37

in Young Children with ADHD. Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006

30. Thomason CK, Riordan HJ, Schaeffer JA, Slagle PK, Cox K, Kratochvil CJ. Antidepressant Prescribing Practices Prior to and After the Black Box Warning. Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006

31. Spencer TJ, Kratochvil CJ, Sangal R, Saylor K, Bailey C, Dunn D, Casat C, Lipetz R, Jain R, Newcorn J, Ruff D, Feldman P, Allen A. Five-Year Effects of Atomoxetine on Growth in Children with ADHD. Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006

32. Lerner M, Wigal SB, Kratochvil CJ, Jiang JG, Earl CQ. Effects of Modafinil in Previously Untreated Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Annual Meeting of the American Academy of Pediatrics, Atlanta, GA, October 7-10, 2006

33. Spencer TJ, Kratochvil, CJ, Ruff DD, Feldman PD. Examination of Methods for Evaluating and Monitoring Growth in ADHD Children: Limitations and Expectations. 17th International Congress of the International Association for Child & Adolescent Psychiatry & Allied Professions, Melbourne, Australia, September 10-14, 2006.

34. Sankaranarayanan J, Puumala SE, Kratochvil CJ. Medication and Behavioral Treatment of Adult Attention-Deficit/Hyperactivity Disorder in United States Ambulatory Care from 1996 to 2003. Academy Health 2006 Annual Research Meeting, Seattle, Washington, June 26, 2006.

35. Kratochvil CJ, Spencer TJ, Ruff DD, Moore RJ, Gaillez C, Allen AJ. Long-term Effects of Atomoxetine on Growth in Children with ADHD. Annual Meeting of the Society of French Pediatricians, June 14-17, 2006 Lyon, France.

36. Wigal SB, Kratochvil CJ, Pliszka SR, Arnold V, Knutson JA, Boellner SW, Earl CQ, Yang R, Jiang JG. Modafinil-ADHD in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Efficacy and Tolerability is Maintained with Long-term Treatment. New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 12-15, 2006.

37. Thomason C, Riordan H, Schaeffer J, Cox K, Kratochvil C. A Review of Antidepressant Prescribing Practices in a Large, National, Managed Care Database of Pediatric Patients Prior to and After Black-Box Warnings. New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 12-15, 2006.

38. Madaan V, Kratochvil CJ, Puubala S, May D, March J. Impact of Attention-Deficit/Hyperactivity Disorder on the Treatment of Depressed Adolescents. Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006.

39. Vaughan BS, Faries DE, Kratochvil CJ, Perwien A, Brown R. Health-Related Quality of Life, Social Skills and Academic Functioning in School-Aged Children with ADHD. 19th Annual Conference of the American Psychiatric Nurses Association, Nashville, TN, November 2-5, 2005.

40. Kratochvil C, Biederman J, Swanson JM, Greenhill L, Earl CQ, Jiang JG. Efficacy of Modafinil Film-coated Tablets (Modafinil-ADHD) in Attention-Deficit/Hyperactivity Disorder Established in Three Randomized Controlled Trials. 17th Annual International Conference on Attention-Deficit/Hyperactivity Disorder, Dallas, TX, October 27-29, 2005.

41. Bhatia SK, Kratochvil CJ, Vitiello B, Sitorius MA, Buehler BA, Rezac AJ. Pediatric Mental Health Resources and Antidepressant Prescribing Practices. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.

42. Wilens T, Kratochvil C, Newcorn J, Gao H. Acute Effects of Atomoxetine in Children versus Adolescents. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.


38

43. Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason C, Rogers AK, Feldman PD, Levine LR. Effects of Longer-Term Atomoxetine Treatment in Adolescents with ADHD. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.

44. Kratochvil CJ, Faries DE, Vaughan BS, Perwien AR, Busner J, Saylor K, Kaplan S, Buermeyer C, Saylor D, Swindel R. Emotional Expression During ADHD Treatment: Initial Assessment of Treatment Effects. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.

45. Kratochvil CJ, Michelson D, Newcorn JH, Moore RJ, Ruff DD, Dickson R, Saylor K, Busner J, Luber S, Turgay A, Weiss M, Vaughan B, Allen AJ. High-Dose Atomoxetine for the Treatment of ADHD. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.

46. Biederman J, Wigal S, Kratochvil C, Swanson J, Greenhill L. Modafinil Film-Coated Tablets Improve Symptoms of Attention-Deficit/Hyperactivity Disorder. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.

47. Newcorn JH, Kratochvil CJ, Allen AJ, Ruff DD, Zhang S, Moore RJ, Michelson D. Low-Dose Atomoxetine for Maintenance Treatment of ADHD. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.

48. Kratochvil CJ, Greenhill LL. Safety and Tolerability of Modafinil in Children and Adolescents with ADHD. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.

49. Newcorn JH, Kratochvil CJ, Allen AJ, Milton DR, Moore RJ, Michelson D. Atomoxetine and OROS Methylphenidate for the Treatment of ADHD: Acute Results and Methodological Issues. New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 6-9, 2005.

50. Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Greenhill LL, Earl CQ, Jiang JG. Safety and Efficacy of Modafinil Film-Coated Tablets in Children and Adolescents with ADHD. New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 6-9, 2005.

51. Kratochvil CJ, Spencer TJ, Ruff DD, Moore RJ, Allen AJ. Long-term Effects of Atomoxetine on Growth in Children with ADHD. Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington D.C., October 19-24, 2004.

52. Kratochvil CJ, Perwien A, Vaughan B, Faries D, Saylor K, Busner J, Bermire C, Wong H, Swindle R. Emotional Expression and ADHD Pharmacotherapy in Children: A New Measure. Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington D.C., October 19-24, 2004.

53. Kratochvil CJ, Greenhill LL, Gao H, Thomason CK, and Gelowitz DL. Long-term Atomoxetine Administration for Young Children with Attention-Deficit/Hyperactivity Disorder. Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, D.C., October 19-24, 2004.

54. Vaughan BS, Faries DE, & Kratochvil C (2004). Health Related Quality of Life in Children with ADHD: Long Term Effects of Atomoxetine. Annual Meeting of the American College of Nurse Practitioners, Philadelphia, PA, October 20-23, 2004.

55. Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Dickson R, and Gelowitz DL. 54th Annual Meeting of the Canadian Psychiatry Association, October 14-17, 2004, Montréal, Quebec Do Children and Adolescents with ADHD Respond Differently to Atomoxetine?

56. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Weiss M, Greenhill LL, Gao H, Weiss M, and Gelowitz DL. Canadian Academy of Child and Adolescent Psychiatry Meeting


39

Montreal, Quebec, October 3- 5, 2004, Effects of Long-term Atomoxetine Treatment for Young Children with ADHD.

57. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Weiss M, Greenhill LL, Gao H, Weiss M, and Gelowitz DL. Effects of Long-term Atomoxetine Treatment for Young Children with ADHD. 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions, Berlin Germany, August 22-26, 2004.

58. Simpson A, Kratochvil CJ, Newcorn JH, Allen AJ, Faries DE, Zhang S, Milton DR, Feldman PD, Schuh KJ, Michelson D, Biederman J. Efficacy of atomoxetine in placebo-controlled studies in children, adolescents, and adults with attention-deficit/hyperactivity disorder. 12th Congress of the Association of European Psychiatrists, Geneva, Switzerland, April 14-18, 2004.

59. Wilens TE, Newcorn J, Kratochvil C, Gelowitz D, Thomason C, Rogers AK. Longer-Term Treatment with Atomoxetine in Adolescents with ADHD. Annual Meeting of the American Psychiatric Association, New York City, NY, May 1-6, 2004.

60. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Thomason CK & Gelowitz DL. Effects of long-term atomoxetine treatment for young children with ADHD. Annual Meeting of the American Psychiatric Association, New York City, NY, May 1-6, 2004.

61. Kratochvil CJ, Greenhill LL, Milton DR, Gelowitz DL, Rogers AK. Acute effects of atomoxetine in different pediatric age categories: a comparative analysis. 59th Annual Meeting of the Society of Biological Psychiatry, New York City, NY, April 29-May 1, 2004.

62. Bylund DB, Deupree JD, Kratochvil CJ, Smith SD, Ellis CR. Alpha-2 adrenergic receptors in attention deficit hyperactivity disorder (ADHD). Experimental Biology 2004, Washington D.C., April 18, 2004.

63. Kratochvil CJ, Newcorn J, Gao H, Michelson D. Atomoxetine for comorbid ADHD and affective symptoms. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.

64. Kratochvil CJ, Milton DR, Vaughan BS, Burke WJ, Jones ED. Atomoxetine in the treatment of young children with ADHD. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.

65. M. Weiss, R Tannock, C Kratochvil, D Dunn, J Velez-Borras, C Thomason, L Lambrecht, R Tamura, D Kelsey, and AJ Allen. Controlled study of once-daily atomoxetine in the school setting. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.

66. Wilens T, McGough J, Kratochvil C, on behalf of the Adolescent Study Group. Tolerability of OROS methylphenidate (MPH) in adolescents with ADHD. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.

67. Perwein AR, Faries D, Kratochvil C, Michelson D: Long-term effects of atomoxetine on health-related quality of life. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.

68. Perwein AR, Faries D, Kratochvil C, Sumner C, Kelsey D, Allen A. Functional outcomes and ADHD: the effect of atomoxetine treatment. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.

69. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Lambrecht L, Tamura R, Kelsey D, Allen, AJ. Placebo-controlled study of once daily atomoxetine in the school setting. European Society of Child and Adolescent Psychiatry; Paris, France; September 28 – October 1, 2003.

70. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Lambrecht L, Tamura R, Kelsey D, Allen, AJ. Placebo-controlled study of once daily atomoxetine in the school setting. European College of Neuropsychopharmacology; Prague, Czech Republic; September 20-24, 2003.


40

71. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, LambrechtL , Tamura R, Kelsey D, & Allen AJ. Controlled study of once-daily atomoxetine in the school setting. Canadian College of Neuropsychopharmacology; Montreal, CA; June 1-4, 2003.

72. Kratochvil CJ, Milton D, Vaughan V, & Burke WJ: Atomoxetine in the treatment of young children with ADHD. New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, May 28, 2003.

73. Kratochvil CJ: A Randomized, Placebo-Controlled Study of Once-Daily Atomoxetine in the School Setting in Children with ADHD. 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 20, 2003.

74. Michelson D, Allen AJ, Kelsey D, Kratochvil C, Newcorn J, Wernicke J: Once-daily atomoxetine treatment for children and adolescents with ADHD. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, San Francisco, CA, October 22-23, 2002.

75. Wernicke JF, Kratochvil C, Michelson D, Milton D, Dunn D, Spencer T, Heiligenstein J: Long-term safety of atomoxetine in the treatment of ADHD. World Psychiatric Congress, Yokohama, Japan, July 17, 2002.

76. Burke WJ, Frank MG, Ranno AE, McArthur-Miller DA, Johnson Dr, Kratochvil CK: A randomized, placebo-controlled trial of citalopram’s effect on natural killer cell activity in major depression. NCDEU 42nd Annual Meeting, Boca Raton, FL, June 10-13, 2002.

77. Vaughan BV, Kratochvil C, Bohac D, & Burke W: Relationship between compliance and long-term efficacy of atomoxetine treatment: One-year data. Nebraska Nurse Practitioner 11th Annual Primary Care Conference, Kearney, NE, February 21-23, 2002.

78. Kratochvil CJ, Heiligenstein J, Dittman R, Spencer T, Biederman J, Wernicke J, Newcorn J, Casat C, Milton D, & Michelson D: Atomoxetine and methylphenidate treatment in ADHD children: a randomized open-label trial. Scientific Proceedings of the 48th Annual American Academy of Child & Adolescent Psychiatry Meeting, Honolulu HI, October 25, 2001

79. Kratochvil CJ, Michelson D, Wernicke J, Heiligenstein J, Spencer T, Allen AJ, Faries D, & Kendrick K: Atomoxetine: a new, non-dopaminergic intervention for ADHD. Scientific Proceedings of the 48th Annual American Academy of Child & Adolescent Psychiatry Meeting, Honolulu, HI, October 25, 2001.

80. Kratochvil, CJ, Wernicke J, Michelson D, Vaughan B, Bohac D, Harrington M, Baker N, May D, & Burke W: Long-term study of atomoxetine in the treatment of ADHD. Scientific Proceedings of the 48th Annual American Academy of Child & Adolescent Psychiatry Meeting, Honolulu, HI, October 25, 2001.

81. Heiligenstein J, Biederman J, Faries D, Galil N, Dittman N, Emslie G, Kratochvil C, Laws H, & West S: Atomoxetine efficacy vs placebo in school-age girls with ADHD. Scientific Proceedings of the 48th Annual American Academy of Child & Adolescent Psychiatry Meeting, Honolulu, HI, October 25, 2001.

82. Kratochvil CJ: ADHD Inside and Outside the Classroom Symposium; Expanding Treatment Options for ADHD. American Academy of Pediatrics, San Francisco, CA, October 21, 2001.

83. Kratochvil CJ, Vaughan B, Bohac D, Harrington MJ, Baker N, May D, & Burke WJ: Long-term efficacy of tomoxetine for pediatric ADHD: 1 year data. Scientific Proceedings of the 41st Annual NCDEU Meeting, Phoenix AZ, May 29, 2001.

84. Heiligenstein JH, Spencer TJ, Faries DE, Beiderman J, Kratochvil C, & Connors CK: Efficacy of atomoxetine vs. placebo in pediatric outpatients with ADHD. Scientific Proceedings of the 47th Annual American Academy of Child & Adolescent Psychiatry Meeting, NY, NY, October 26, 2000.


41

85. Kratochvil CJ, Harrington M, Baker N, Bohac D, May D, & Burke W: A open-label trial of atomoxetine in pediatric ADHD. Scientific Proceedings of the 47th Annual American Academy of Child & Adolescent Psychiatry Meeting, NY, NY, October 26, 2000.

86. Heiligenstein JH, Spencer TJ, Farien DE, Biederman J, Kratochvil C, Conners, CK: Efficacy of Tomoxetine vs. Placebo in Pediatric Outpatients with ADHD. Presented at American Academy of Child & Adolescent Psychiatry Annual Meeting, NY, NY, October 26, 2000

87. Kratochvil CK, Harrington M, Baker N, Bohac D, May D, Burke W: An Open Label Trial of Tomoxetine in Pediatric ADHD. Presented at American Academy of Child & Adolescent Psychiatry Annual Meeting, NY, NY, October 26, 2000

Book Reviews Kratochvil CJ (2008). Your Child in the Balance: An Insider’s Guide for Parents to the Psychiatric Medicine Dilemma, Kalikow KT, CDS Books, Psychiatric Times, 25(3):66. Madaan V & Kratochvil CJ (2006). Attention Deficit Disorder: The Unfocused Mind in Children and Adults, Brown TE, Yale University Press, J Am Acad Child Adolesc Psychiatry, 45(12):. Lay Press & Non-Peer Reviewed Lubberstedt B, Vaughan BS, Kratochvil CJ (2006) Treatment of Preschool ADHD: Overview of

the Preschool ADHD Treatment Study (PATS). Child & Adolescent Psychopharmacology News

Madaan V & Kratochvil CJ (2005). Hot Topics in ADHD: Pharmacology Update. Developmental and Behavioral News, 14(2): 6-7.

Kratochvil CJ (2005). Understanding Phases of Drug Development. Attention! For Families & Adults with Attention-Deficit/Hyperactivity Disorder, 12(2):50-51.

Lectures In Team-Taught Courses Medical Students University of Nebraska Medical Center, Psychiatry Clerkship. 8 lectures annually, 2005-2007 M2 Core Curriculum, University of Nebraska Medical School, Omaha, NE, 2 lectures annually,

2000- Present Creighton University School of Medicine, Pediatrics Clerkship, 8 lectures annually, 1998- 2004 Residents

• Psychiatry Residents, UNMC/Creighton: 4 lectures annually

• Child Psychiatry Residents, UNMC/Creighton: 16 lectures annually UNMC Fellows Introduction to the Institutional Review Board, Clinical Research Symposium, University of

Nebraska Medical Center, Omaha, NE, annually 2001- 2010 Allied Health Students, UNMC Introduction to the Institutional Review Board and Human Subjects Protections, University of

Nebraska Medical Center, Omaha, NE, annually 2001- 2009 Courses Coordinated Pediatric Psychopharmacology, Child & Adolescent Psychiatry Residents, Creighton-Nebraska

Joint Residency Program, 2000- 2010 Psychopharmacology Update Child & Adolescent Psychiatry Residents, Creighton-Nebraska

Joint Residency Program, 2000- 2010 Cognitive Behavioral Therapy Child & Adolescent Psychiatry Residents, Creighton-Nebraska

Joint Residency Program, 2000- 2001 Graduate Students


42

Supervisory Committee for Ph.D. Candidate Betsy Becker, PT, 2015-Present Supervisory Committee for Ph.D. Candidate Narda Ligotti 2011-2012 Supervisory Committee for Ph.D. Candidate Jeff D. Sanders, 2001-2003 Mentorship Soonjo Hwang, IDEA-CTR Mentorship, 2017 - present Supriya Bhatia, Spurlock Minority Medical Student Fellowship, American Academy of Child &

Adolescent Psychiatry, 2005

curriculum vitae christopher jon kratochvil, md unmc cv 2015.pdfcurriculum vitae christopher jon...

Documents